Compounds of formula R.sup.1 CO--NH--CH(R.sup.2)--CONH--CH(R.sup.3)--X [wherein: R.sup.1 represents alkyl having an .alpha.-amino or protected .alpha.-amino substituent and an aryl, heterocyclic or heterocyclic-dithio substituent; R.sup.2 represents a variety of aliphatic and cycloaliphatic hydrocarbon groups, which may be substituted; R.sup.3 represents isobutyl, sec-butyl, benzyl or (C.sub.3 -C.sub.8 cycloalkyl)methyl; and X represents a group of formula --CH(--A--R.sup.4)--Y (in which: A represents a single bond or an alkylene group; R.sup.4 represents a carboxy group; a protected carboxy group, a carbamoyl group, an N-substituted carbamoyl group, a carbazoyl group, an N-substituted carbazoyl group or an acyl group; and Y represents a hydroxy group, a mercapto group or a formyl group), or a group of formula --P(O) (R.sup.5)--OH (in which R.sup.5 represents a substituted alkyl group having at least one substituent selected from carboxy groups, protected carboxy groups, N-substituted carbamoyl groups, carbazoyl groups, N-substituted carbazoyl groups, C.sub.2 -C.sub.7 aliphatic carboxylic acyl groups and aromatic carboxylic acyl groups)]; and their salts are renin inhibitors, which may be used in the treatment of angiotensin-induced hypertension.

Description

45 parts

›BACKGROUND OF THE INVENTION

The present invention relates to a series of new hypotensive peptides which are of particular value in the treatment of hypertension induced by failures in the renin-angiotensin system, and to their use in such treatment.

There is considerable evidence that reduction of elevated blood pressure reduces the risks of morbidity and mortality. Elevated blood pressure (hypertension) can be caused by a variety of factors and a large number of drugs are available for the treatment of hypertension, the drug of choice being dictated in large measure by the cause of the hypertension. Angiotensin I is a polypeptide formed by the action of renin upon a plasma protein and is converted to angiotensin II by the action of ACE. Angiotensin II causes constriction of the arterioles and can produce hypertension. Hypertension of this type can be reduced by reducing the plasma concentration of angiotensin which, in turn, can be achieved by inhibiting the activity of renin. The number of available drugs having this type of inhibitory activity is very limited.

Certain peptide derivatives having this type of activity are disclosed in Japanese Patent Application Kokai No. 151166/77 and may be represented by the formula R a CO--X--His--NH--CH(CH 2 R b )--CHO, in which R a and R b represent various organic groups and His represents the L-histidyl group.

Other polypeptides which have been proposed for use as renin inhibitors are the angiotensinogen fragments described by Szelke et al. [Nature, 299, 555 (1982)] and the statine derivatives described by Boger et al. [Nature, 303, 81 (1983)].

Certain hypotensive peptides closely related to the compounds of the present invention are disclosed in copending U.S. patent application Ser. No. 618,127, filed on 7th June 1984 by the present inventors, now U.S. Pat. No. 4,548,926.

We have now discovered a series of peptide derivatives having a very marked ability to inhibit the activity of renin.

›BRIEF SUMMARY OF INVENTION

The compounds of the invention are peptides having the general formula (I):

R.sup.1 CO--NH--CH(R.sup.2)--CONH--CH(R.sup.3)--X (I)

[wherein:

R 1 represents a C 1 -C 4 alkyl group having:

(a) an amino or protected amino substituent on its α-carbon atom and

(b) a carbocyclic aromatic substituent, a heterocyclic substituent or a heterocyclic-dithio substituent wherein the aromatic or heterocyclic ring is unsubstituted or has at least one substituent selected from the group consisting of amino groups, alkyl groups, hydroxy groups, alkoxy groups, halogen atoms, nitro groups, mercapto groups and alkylthio groups;

R 2 represents hydrogen, a C 1 -C 18 alkyl group, a C 2 -C 5 alkenyl group, a C 2 -C 5 alkenyl group having at least one halogen substituent, a C 2 -C 5 alkynyl group, a C 3 -C 7 cycloalkyl group, a C 5 -C 8 cycloalkenyl group, a C 1 -C 4 alkyl group having one substituent selected from the group consisting of:

(c) C 3 -C 7 cycloalkyl groups, C 5 -C 8 cycloalkenyl groups, aryl groups and 5- and 6 -membered heterocyclic groups having at least one hetero-atom selected from the group consisting of sulfur, nitrogen and oxygen atoms

or a C 1 -C 4 alkyl group having one substituent selected from the group consisting of:

(c) C 3 -C 7 cycloalkyl groups, C 5 -C 8 cycloalkenyl groups, aryl groups and 5- and 6-membered heterocyclic groups having at least one hetero-atom selected from the group consisting of sulfur, nitrogen and oxygen atoms and

at least one substituent selected from the group consisting of:

(d) halogen atoms, hydroxy groups, alkoxy groups, aryloxy groups, aralkyloxy groups, aliphatic carboxylic acyloxy groups, mercapto groups, alkylthio groups, aliphatic carboxylic acylaminoalkylthio groups, arylthio groups, aralkylthio groups, alkylsulfinyl groups, alkylsulfonyl groups, arylsulfinyl groups, arylsulfonyl groups, amino groups, mono- and di-alkylamino groups, arylamino groups, aliphatic carboxylic acylamino groups, aromatic carboxylic acylamino groups, alkoxycarbonylamino groups, aralkyloxycarbonylamino groups, aliphatic carboxylic acyl groups, aromatic carboxylic acyl groups, carboxy groups, alkoxycarbonyl groups, aralkyloxycarbonyl groups, carbamoyl groups, mono- and di-alkylcarbamoyl groups, ureido groups, thioureido groups and guanidyl groups;

R 3 represents an isobutyl, sec-butyl, benzyl or (C 3 -C 8 cycloalkyl)methyl group;

X represents a group of formula --CH(--A--R 4 )--Y (in which: A represents a single bond or an alkylene group; R 4 represents a carboxy group; a protected carboxy group, a carbamoyl group, an N-substituted carbamoyl group, a carbazoyl group, an N-substituted carbazoyl group or an acyl group; and Y represents a hydroxy group, a mercapto group or a formyl group), or

a group of formula --P(O)(R 5 )--OH (in which R 5 represents a substituted alkyl group having at least one substituent selected from carboxy groups, protected carboxy groups, N-substituted carbamoyl groups, carbazoyl groups, N-substituted carbazoyl groups, C 2 -C 7 aliphatic carboxylic acyl groups and aromatic carboxylic acyl groups);

provided that, where A represents an alkylene group and

R 2 represents a 4-imidazolylmethyl group, R 4 does not represent a carbamoyl group or a formyl group];

and pharmaceutically acceptable salts thereof.

The invention also provides a method of treating angiotensin-induced hypertension in a mammal, which may be human or non-human, by administering to said mammal an effective amount of a renin inhibitor, wherein said renin inhibitor is selected from the group consisting of compounds of formula (I) and pharmaceutically acceptable salts thereof.

›DETAILED DESCRIPTION OF INVENTION · 1 of 16

In the compounds of the invention, where R 1 represents an alkyl group having an aryl substituent, the aryl substituent is preferably a phenyl or 1- or 2-naphthyl group and the alkyl group is a C 1 -C 4 alkyl group, preferably a C 1 or C 2 alkyl group. Preferred such groups represented by R 1 are the α-aminobenzyl, α-aminophenethyl, 1-amino-3-phenylpropyl, 1-amino-2-(1-naphthyl)ethyl and 1-amino-2-(2-naphthyl)ethyl groups, in which the amino groups are free or protected, and in which the aryl groups may be substituted or unsubstituted, e.g. by hydroxy, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, nitro, halo (e.g. chloro) or amino groups.

Where R 1 is an alkyl group (having from 1 to 4 and preferably 1 or 2 carbon atoms) having a heterocyclic substituent, the heterocyclic substituent preferably has from 4 to 8, more preferably 5, 6, 7 or 8, ring atoms, and has one or more hetero-atoms selected from the group consisting of nitrogen, oxygen and sulfur, preferably nitrogen. Particularly preferred heterocyclic groups are: the pyridyl groups, especially the 2-, 3- and 4-pyridyl groups; the quinolyl groups, especially the 3-, 4-, 5- and 8-quinolyl groups; the indolyl groups, especially the 2- and 3-indolyl groups; and the isoquinolyl groups. These heterocyclic groups may be unsubstituted or may have one or more substituents. Where they are substituted, preferred substituents are hydroxy groups, C 1 -C 4 alkyl groups, halogen atoms, amino groups and nitro groups. Preferred substituted heterocyclic groups are the nitropyridyl groups.

Where R 1 is an alkyl group having a heterocyclicdithio substituent, the heterocyclic group may be any one of those listed above, but is preferably a pyridyl group (2-, 3- or 4-pyridyl) optionally having one of the substituents mentioned above, preferably a nitro substituent.

The C 1 -C 4 alkyl group represented by R 1 has, in addition to the aromatic or heterocyclic substituent, also a substituent (a) which is an amino group or a protected amino group. The amino group or protected amino group is on the α-carbon atom of the alkanoyl group represented by R 1 CO--. The nature of the protecting group is not critical to the present invention and any protecting group commonly used in this field may be employed. Non-limiting examples of such protecting groups include the following:

alkoxycarbonyl groups, preferably (C 1 -C 6 alkoxy)carbonyl groups and more preferably (C 3 -C 5 alkoxy)carbonyl groups, most preferably (C 4 or C 5 alkoxy)carbonyl groups, for example the methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, sec-butoxycarbonyl, isobutoxycarbonyl or t-butoxycarbonyl or t-amyloxycarbonyl groups, of which the t-butoxycarbonyl or t-amyloxycarbonyl groups are the most preferred;

substituted alkoxycarbonyl groups, especially alkoxy-substituted groups (in which the alkoxy group itself may be substituted, preferably by another alkoxy group); the preferred groups are substituted ethoxycarbonyl groups, more preferably optionally substituted ethoxyethoxycarbonyl groups, and most preferably the 2-(2-methoxyethoxy)ethoxycarbonyl group;

alkanoyl groups, which may be straight or branched chain groups, and which preferably have from 2 to 7 carbon atoms (which number includes the carbon atom of the carbonyl group), more preferably 3 or 4 carbon atoms, for example the acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl or heptanoyl groups, more preferably the propionyl or butyryl groups;

alkoxycarbonyl or alkanoyl groups, such as those listed above, having an aryl or heterocyclic substituent, which itself may be substituted; aryl substituents are carbocyclic aryl groups, preferably having from 6 to 14 carbon atoms, and more preferably having 6, 10 or 13 carbon atoms, for example the phenyl, naphthyl (1- or 2-naphthyl) or fluorenyl (preferably 9-fluorenyl) groups; preferred heterocyclic substituents include the pyridyl groups, preferably the 2- and 3-pyridyl groups; examples of substituents on the aryl and heterocyclic groups are given hereafter; preferred examples of such substituted alkoxycarbonyl and alkanoyl groups include the benzyloxycarbonyl, 3-phenylpropionyl, 4-phenylbutyryl, 3-(1-naphthyl)propionyl and 3-pyrid-2-ylpropionyl groups;

alkanoyl or alkoxycarbonyl groups (which may be as exemplified above) having an aryldithio or heterocyclic-dithio substituent; examples of aryl and heterocyclic groups, which may be substituted, are given above; the preferred groups are the pyridyldithiopropionyl, phenyldithiopropionyl and 3-(3-nitropyrid-2-yldithio)propionyl groups;

arylthio and heterocyclic-thio groups, in which the aryl and heterocyclic groups, which may be substituted, are preferably as exemplified above; preferred groups are the phenylthio, pyridylthio (especially 2-pyridylthio and 3-pyridylthio), 2-nitrophenylthio and 3-nitropyrid-2-ylthio groups; and

amino acid residues, in which the amino group is protected by any one of the protecting groups referred to herein, particularly those referred to above, for example the alanyl, β-alanyl, glycyl, histidyl, homoseryl, isoleucyl, leucyl, lysyl, methionyl, norleucyl, norvalyl, ornithyl, sarcosyl, thyronyl, tyrosyl, valyl and tryptophyl groups, and such groups having aryl (as exemplified above) substituents, such as the phenylalanyl, chlorophenylalanyl, especially p-chlorophenylalanyl, and 3-naphthylalanyl, especially 3-(1-naphthyl)alanyl, groups; these groups may be L, DL or D and the preferred groups are the phenylalanyl, tryptophyl and 3-(1-naphthyl)alanyl groups, particularly the L-isomers.

Particularly preferred examples of acyl groups which may be represented by R 1 CO-- are the phenylalanyl, N-(benzyloxycarbonyl)phenylalanyl, N-(benzyloxycarbonyl)-(p-nitrophenyl)alanyl, N-(benzyloxycarbonyl)-(p-chlorophenyl)alanyl, 3-(1-naphthyl)alanyl, N-(benzyloxycarbonyl)phenylglycyl, N-(4-phenylbutyryl)phenylalanyl, N-benzyloxycarbonyl-3-(3-quinolyl)alanyl, N-benzyloxycarbonyl-3-(4-quinolyl)alanyl, N-(benzyloxycarbonyl)tyrosyl, N-(2-nitrophenylthio)phenylalanyl, N-(3-nitropyrid-2-ylthio)phenylalanyl, N-benzyloxycarbonyl-3-(1-naphthyl)alanyl, N-benzyloxycarbonyl-3-(2-naphthyl)alanyl, N-benzyloxycarbonyl-3-(5-quinolyl)alanyl, N-benzyloxycarbonyl-3-(8-quinolyl)alanyl, N-(t-butoxycarbonyl)-S-(3-nitropyrid-2-ylthio)cysteinyl, N-(9-fluorenylmethoxycarbonyl)phenylalanyl, N-[N-(benzyloxycarbonyl)phenylalanyl]phenylalanyl, N-[N-(benzyloxycarbonyl)-3-(1-naphthyl)alanyl]-3-(1-naphthyl)alanyl, N-(benzyloxycarbonyl)tryptophyl and N-(benzyloxycarbonyl)-3-(3-pyridyl)alanyl groups.

›DETAILED DESCRIPTION OF INVENTION · 2 of 16

The alanyl, glycyl, tyrosyl, cysteinyl and tryptophyl groups referred to above may be D, DL or L (and, where there are 2 or more of them, they may be the same or different), but they are preferably L.

Where R 2 represents an unsubstituted alkyl group, this may be a straight or branched chain alkyl group and has from 1 to 18 carbon atoms, more preferably from 1 to 10 carbon atoms. Examples of such groups include the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, isopentyl, neopentyl, t-pentyl, hexyl, isohexyl, 2-methylbutyl, 2-methylpentyl, heptyl, octyl, 2-ethylhexyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl and octadecyl groups. Of these, the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, pentyl, heptyl and decyl groups are preferred.

Where R 2 represents an unsubstituted alkenyl group, this has from 2 to 5 carbon atoms and may be a straight or branched chain group. Examples of such groups include the vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl and 4-pentenyl groups, of which the vinyl and allyl, especially the allyl, groups are preferred. Where R 2 represents a halogen-substituted alkenyl group, the halogen substituent may be a chlorine, fluorine, bromine or iodine atom, preferably a chlorine atom, and the alkenyl group may bear one or more, preferably from 1 to 3, such substituents.

Where R 2 represents a C 2 -C 5 alkynyl group, this may be a straight or branched chain group and examples include the ethynyl, 1-propynyl, propargyl (i.e. 2-propynyl), 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl and 4-pentynyl groups, of which the propargyl group is preferred.

Where R 2 represents a C 3 -C 7 cycloalkyl group or a C 1 -C 4 alkyl group having a C 3 -C 7 cycloalkyl substituent, the alkyl group may be any one of the C 1 -C 4 alkyl groups listed in relation to R 2 itself and the cycloalkyl group may be a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl group. The cycloalkyl group represented by R 2 is preferably a cyclopropyl, cyclopentyl or cyclohexyl group and the cycloalkyl-alkyl groups are preferably the cyclopropylmethyl, cyclopentylmethyl and cyclohexylmethyl groups.

Where R 2 represents a C 5 -C 8 cycloalkenyl group or an alkyl group having a C 5 -C 8 cycloalkenyl substituent, the cycloalkenyl group is preferably a cyclopentenyl (1-, 2- or 3-cyclopentenyl), a cyclohexenyl (1-, 2- or 3-cyclohexenyl) group or a cycloheptenyl (1-, 2-, 3- or 4-cycloheptenyl) group. In the case of the cycloalkenyl-alkyl groups, the alkyl group is preferably a methyl group.

Where R 2 represents an aralkyl group, the alkyl group has from 1 to 4 carbon atoms and may be a straight or branched chain group, for example the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or t-butyl group, preferably a methyl or ethyl group. The aryl group is an aromatic carbocyclic group, which may have 1, 2 or 3 fused rings. The preferred aryl groups are the phenyl and naphthyl (1- or 2-naphthyl) groups and the preferred aralkyl groups are the benzyl, phenethyl, 1-naphthylmethyl and 2-naphthylmethyl groups; the aryl portions of these aralkyl groups may be substituted or unsubstituted, and, if substituted, the substituents may be chosen from those listed hereafter in relation to aryl groups.

Where R 2 represents an alkyl group having a heterocyclic substituent, the heterocyclic ring contains 5 or 6 ring atoms, of which at least 1 (and preferably from 1 to 4) are hetero-atoms selected from the group consisting of sulfur, nitrogen and oxygen atoms. Examples of such heterocyclic groups are the indolyl (preferably 2- or 3-indolyl), thienyl (preferably 2-thienyl), thiazolyl (preferably 2- or 4-thiazolyl), pyridyl (2-, 3- or 4-pyridyl), pyrrolidinyl (preferably 2-pyrrolidinyl), thiazolidinyl (preferably 1,3-thiazolidin-4-yl), imidazolyl (preferably 4-imidazolyl), furyl (e.g. 2-furyl), quinolyl (e.g. 3-, 4-, 5- or 8-quinolyl) or piperidyl (e.g. 2-piperidyl) groups; the heterocyclic rings may be substituted or unsubstituted, and, if substituted, the substituents may be chosen from those listed hereafter.

The heterocyclic and aryl groups which may be substituents on the alkyl groups represented by R 2 may be themselves substituted and, if substituted, the substituents may be as described hereafter, but are preferably C 1 -C 4 alkyl (particularly methyl) groups.

In addition to the aryl and heterocyclic groups mentioned above, R 2 may also have one or more other substituents on its alkyl group. Where the other substituent is a halogen atom, this is preferably a chlorine, bromine, fluorine or iodine atom and there may be one or more of these atoms as substituents. In particular, the alkyl group may, if desired, have three of these halogen substituents on a single carbon atom, for example three fluorine or chlorine substituents.

Where the alkyl group has an alkoxy substituent, this is preferably a C 1 -C 4 alkoxy substituent, for example a methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy or t-butoxy group.

Where the alkyl group represented by R 2 has an aryloxy group as the substituent, this is a carbocyclic aryloxy group and preferably has 1 or 2 carbocyclic rings, more preferably a phenoxy group. The aryloxy group may, if desired, be substituted by any one or more of the substituents hereafter described in relation to aryl groups.

Where the substituent on R 2 is an alkylthio group, this is preferably a C 1 -C 4 alkylthio group, for example a methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio or t-butylthio group.

Where the substituent on R 2 is an aliphatic carboxylic acylaminoalkylthio group, the aliphatic acyl group thereof may be any one of the C 1 -C 7 alkanoyl groups hereafter described in relation to R 4 .

Where the substituent on R 2 is an arylthio group, the aryl group is a carbocyclic aromatic group, preferably having 1 or 2 carbocyclic rings, preferably a phenyl group; this may be unsubstituted or it may be substituted as described hereafter in relation to aryl groups.

›DETAILED DESCRIPTION OF INVENTION · 3 of 16

Where the substituent on R 2 is an aralkylthio group, the aralkyl group is preferably one of those described above in relation to R 2 itself, but is more preferably a benzylthio, phenethylthio or naphthylmethylthio group and the aryl group may be substituted or unsubstituted; if substituted, the substituents may be any of those described hereafter in relation to aryl groups.

Where the substituent on R 2 is an alkylsulfinyl group, this is preferably a C 1 -C 4 alkylsulfinyl group, for example a methylsulfinyl, ethylsulfinyl, propylsulfinyl, isopropylsulfinyl, butylsulfinyl, isobutylsulfinyl, sec-butylsulfinyl or t-butylsulfinyl group.

Where the substituent on R 2 is an arylsulfinyl group, the aryl group is a carbocyclic aromatic group preferably having 1 or 2 carbocyclic rings and being optionally substituted as described hereafter in relation to aryl groups. Examples of such arylsulfinyl groups are the benzenesulfinyl, naphthalenesulfinyl and p-toluenesulfinyl groups.

Where the substituent on R 2 is an alkylsulfonyl group, this is preferably a C 1 -C 4 alkylsulfonyl group, for example a methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, isobutylsulfonyl, sec-butylsulfonyl or t-butylsulfonyl group.

Where the substituent on R 2 is an arylsulfonyl group, the aryl group is a carbocyclic aromatic group, preferably having 1 or 2 carbocyclic rings and being substituted or unsubstituted; if substituted, the substituents may be as described hereafter in relation to aryl groups. Preferred examples of such arylsulfonyl groups are the benzenesulfonyl, naphthalenesulfonyl and p-toluenesulfonyl groups.

Where the substituent on R 2 is a mono- or di-alkylamino group, the or each alkyl group is preferably a C 1 -C 4 alkyl group, which may be a straight or branched chain group. Preferred examples of such alkylamino groups include the methylamino, dimethylamino, ethylamino, diethylamino, methylethylamino, propylamino, dipropylamino, methylpropylamino, isopropylamino, butylamino, dibutylamino, methylbutylamino, isobutylamino, sec-butylamino and t-butylamino groups.

Where the substituent on R 2 is an aliphatic carboxylic acylamino group, this is preferably a C 1 -C 7 alkanoylamino group, for example a formamido, acetamido, propionamido, butyramido, isobutyramido, valeramido, isovaleramido, pivalamido or hexanamido group.

Where the substituent on R 2 is an alkoxycarbonylamino group, the alkoxy group may be a straight or branched chain group and preferably has from 1 to 4 carbon atoms. Examples of such groups include the methoxycarbonylamino, ethoxycarbonylamino, propoxycarbonylamino, isopropoxycarbonylamino, butoxycarbonylamino, isobutoxycarbonylamino, sec-butoxycarbonylamino and t-butoxycarbonylamino groups, more preferably the t-butoxycarbonylamino group.

Where the substituent on R 2 is an aralkyloxycarbonylamino group, the aryl group thereof is a carbocyclic aromatic group, preferably having 1 or 2 carbocyclic rings, and which may be unsubstituted or substituted (as described hereafter in relation to aryl groups). The alkyl group thereof is preferably a C 1 -C 4 alkyl group, more preferably a C 1 -C 3 alkyl group, examples of which are given above in relation to R 2 itself; the preferred groups are the straight-chain groups, particularly the methyl, ethyl and propyl groups and examples of such aralkyloxycarbonylamino groups are the benzyloxycarbonylamino, phenethyloxycarbonylamino and 3-phenylpropoxycarbonylamino groups, preferably the benzyloxycarbonylamino group.

Where the substituent on R 2 is an aliphatic carboxylic acyl group, this is preferably a C 1 -C 7 alkanoyl group, for example a formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl or heptanoyl group.

Where the substituent on R 2 is an aromatic acyl group, the aromatic ring is a carbocyclic aromatic ring, preferably having 1 or 2 such rings. The preferred aromatic acyl group is the benzoyl group, which may be unsubstituted or may have one or more substituents, as described hereafter in relation to aryl groups.

Where the substituent on R 2 is an alkoxycarbonyl group, the alkoxy group thereof is preferably a C 1 -C 4 alkoxy group and examples of such alkoxycarbonyl groups are the methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl and t-butoxycarbonyl groups.

Where the substituent on R 2 is an aryloxycarbonyl group, the aryl group is an aromatic carbocyclic group, which preferably has 1 or 2 carbocyclic rings. It may be substituted or unsubstituted, as described hereafter in relation to aryl groups, and the preferred aryloxycarbonyl group is the phenoxycarbonyl group.

Where the substituent on R 2 is an aralkyloxycarbonyl group, the aryl group thereof is a carbocyclic aromatic group, which preferably has 1 or 2 carbocyclic rings, preferably a phenyl group. The alkyl group thereof is preferably a C 1 -C 4 alkyl group (examples of which are given in relation to R 2 itself), but is preferably a straight-chain group, particularly the methyl, ethyl or propyl group. Examples of such aralkyloxycarbonyl groups are the benzyloxycarbonyl and phenethyloxycarbonyl groups.

Where the substituent on R 2 is a mono- or di-alkylcarbamoyl group, the alkyl group thereof is preferably a C 1 -C 4 alkyl group (examples of which are given in relation to R 2 itself) and examples of such carbamoyl groups are the methylcarbamoyl, ethylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, methylethylcarbamoyl, propylcarbamoyl, dipropylcarbamoyl, methylpropylcarbamoyl, isopropylcarbamoyl, butylcarbamoyl, isobutylcarbamoyl, sec-butylcarbamoyl and t-butylcarbamoyl groups.

In the compounds of the invention, R 3 represents an isobutyl, sec-butyl, benzyl or (C 3 -C 8 cycloalkyl)methyl group. Where R 3 represents a (C 3 -C 8 cycloalkyl)methyl group, this may be a cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl or cyclooctylmethyl group and is more preferably a cyclopropylmethyl, cyclopentylmethyl or cyclohexylmethyl group, most preferably a cyclopentylmethyl or cyclohexylmethyl group. However, R 3 is preferably an isobutyl or sec-butyl group, more preferably an isobutyl group.

›DETAILED DESCRIPTION OF INVENTION · 4 of 16

Where X represents a group of formula --CH(--A--R 4 )--Y, A may represent a single bond, i.e. X represents a group of formula --CH(R 4 A)--Y, or it may represent an alkylene group. Where A represents an alkylene group, this preferably has from 1 to 8 carbon atoms and examples include the methylene, ethylene, ethylidene, propylidene, isopropylidene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene and octamethylene groups. Of these, A is preferably a C 1 -C 3 alkylene group, particularly the methylene or ethylene group.

R 4 preferably represents a group of formula --COOR 6 (i.e. carboxy or protected carboxy), --CONR 7 R 8 (i.e. carbamoyl or protected carbamoyl), --CONHNR 9 R 10 (i.e. carbazoyl or substituted carbazoyl) or --COR 11 (i.e. acyl).

Where R 4 represents a group of formula --COOR 6 , R 6 represents: a hydrogen atom, a C 1 -C 6 , preferably C 2 -C 5 , alkyl group, for example an ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or 2-methylbutyl group; a carbocyclic aryl group having from 1 to 3 carbocyclic rings, preferably a phenyl group, which may be substituted or unsubstituted, the substituents being as defined hereafter; an aralkyl group, of which the alkyl moiety has from 1 to 4 (preferably 1 or 2) carbon atoms and the aryl moiety has from 1 to 3 (preferably 1) carbocyclic rings, the aralkyl group being substituted or unsubstituted and the substituents being as defined hereafter; or an acyloxymethyl group, wherein the acyl group is a C 1 -C 5 aliphatic carboxylic acyl group or a benzoyl group which may be substituted or unsubstituted, the substituents being as defined hereafter.

Where R 4 represents a group of formula --CONR 7 R 8 , R 7 and R 8 may be the same or different and each represents: hydrogen; a C 1 -C 10 , preferably C 2 -C 8 , alkyl group which may be unsubstituted or may have one or more halogen or hydroxy substituents, for example the methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, 2-methylbutyl, 1-hydroxymethyl-2-methylbutyl or 2,4-dihydroxy-1-(isobutyl)butyl groups; an aralkyl group which is as defined for R 6 ; a diaryl-alkyl group, wherein the aryl and alkyl moieties are each as defined for the respective moieties of the aralkyl group represented by R 6 ; a heterocyclic-substituted methyl or ethyl group, wherein the heterocyclic group has 5 or 6 ring atoms, is saturated or unsaturated and has from 1 to 3 hetero-atoms selected from nitrogen, sulfur and oxygen atoms, preferably a pyridylethyl group; a heterocyclic group having 5 or 6 ring atoms and from 1 to 3 hetero-atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms, and which may be saturated or unsaturated (preferably saturated) and substituted or unsubstituted, the substituents being as defined hereafter, a preferred such heterocyclic group is the piperidyl group; or R 7 and R 8 , together with the nitrogen atom to which they are attached, may represent a nitrogen-containing heterocyclic group having 5 or 6 ring atoms and having, in addition to the said nitrogen atom, 0, 1 or 2 additional hetero-atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms, and which may be saturated or unsaturated and substituted or unsubstituted (the substituents being as defined hereafter), preferred such heterocyclic groups are the piperazinyl and piperidyl groups. Except where R 7 and R 8 together represent said heterocyclic group, we prefer that R 7 should represent a hydrogen atom and R 8 should represent one of the groups defined above.

Where R 4 represents a group of formula --CONHNR 9 R 10 , R 9 and R 10 may be the same or different and each represents: hydrogen; a C 1 -C 6 , preferably C 1 -C 4 alkyl group, preferably the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl or sec-butyl groups, more preferably the methyl or butyl groups; a C 1 -C 7 alkanoyl group, preferably an acetyl or propionyl group; a C 2 -C 9 alkanoyl group having at its ω position an aryl or arylcarbonyl group, wherein the aryl group has from 1 to 3 carbocyclic rings and is substituted or unsubstituted, the substituents being as defined hereafter, preferably a phenyl group.

Where R 4 represents a group of formula --COR 11 , R 11 represents: hydrogen; a C 1 -C 6 , preferably C 1 -C 4 , alkyl group, preferably the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl or sec-butyl groups, more preferably the methyl or butyl groups; or an aryl group having from 1 to 3 carbocyclic rings and being substituted or unsubstituted, the substituents being as defined hereafter.

Preferred examples of such groups which may be represented by X include the 1-hydroxy-ω-carboxyalkyl, 1-hydroxy-ω-methoxycarbonylalkyl, 1-hydroxy-ω-ethoxycarbonylalkyl, 1-hydroxy-ω-butoxycarbonylalkyl, 1-hydroxy-ω-isobutoxycarbonylalkyl, 1-hydroxy-ω-sec-butoxycarbonylalkyl, 1-hydroxy-ω-(2-methylbutoxy)carbonylalkyl, 1-hydroxy-ω-phenoxycarbonyalkyl, 1-hydroxy-ω-benzyloxycarbonylalkyl, 1-hydroxy-ω-phenacyloxycarbonylalkyl, 1-hydroxy-ω-(4-bromobenzyloxycarbonyl)alkyl, 1-hydroxy-ω-carbamoylalkyl, 1-hydroxy-ω-(N-methylcarbamoyl)alkyl, 1-hydroxy-ω-(N-ethylcarbamoyl)alkyl, 1-hydroxy-ω-(N-butylcarbamoyl)alkyl, 1-hydroxy-ω-(N-benzylcarbamoyl)alkyl, 1-hydroxy-ω-(N-sec-butylcarbamoyl)alkyl, 1-hydroxy-ω-[N-(2-methylbutyl)carbamoyl]alkyl, 1-hydroxy-ω-[N-(1-hydroxymethyl-2-methyllbutyl)carbamoyl]alkyl, 1-hydroxy-ω-[N-(4-methoxybenzyl)carbamoyl]alkyl, 1-hydroxy-ω-[N-(4-chlorobenzyl)carbamoyl]alkyl, 1-hydroxy-ω-[N-(2-phenylethyl)carbamoyl]alkyl, 1-hydroxy-ω-[N-(2-phenylpropyl)carbamoyl]alkyl, 1-hydroxy-ω-[N-(1,2-diphenylethyl)carbamoyl]alkyl, 1-hydroxy-ω-[N-(2-pyrid-2-ylethyl)carbamoyl]alkyl, 1-hydroxy-ω-[N-(2-pyrid-4-ylethyl)carbamoyl]alkyl, 1-hydroxy-ω-[N-(1-benzylpiperid-4-yl)carbamoyl]alkyl, 1-hydroxy-ω-[N-(2-morpholinoethyl)carbamoyl]alkyl, 1-hydroxy-ω-{N-[1-(4-methoxybenzyl]-4-piperidyl]carbamoyl}alkyl, 1-hydroxy-ω-(4-phenyl-1-piperazinylcarbonyl)alkyl, 1-hydroxy-ω-(4-benzyl-1-piperazinylcarbonyl)alkyl, 1-hydroxy-ω-[4-(m-tolyl)-1-piperazinylcarbonyl]alkyl, 1-hydroxy-ω-(4-phenylpiperidinocarbonyl)alkyl, 1-hydroxy-ω-carbazolylalkyl, 1-hydroxy-ω-(N 2 -methylcarbazoyl)alkyl, 1-hydroxy-ω-(N 2 -butylcarbazoyl)alkyl, 1-hydroxy-ω-(N 2 -propionylcarbazoyl)alkyl, 1-hydroxy-ω-[N 2 -(ω-phenylalkylcarbonyl)carbazoyl]alkyl, 1-hydroxy-ω-[N 2 -(ω-benzoylalkylcarbonyl)carbazoyl]alkyl, 1-hydroxy-ω-propionylalkyl, 1-hydroxy-ω-benzoylalkyl, 1-mercapto-ω-ethoxycarbonylalkyl, 1-mercapto-ω-[N-(2-methylbutyl)carbamoyl]alkyl, 1-mercapto-ω-[N-(1-hydroxy-2-methylbutyl)carbamoyl]alkyl, 1-mercapto-ω-(N-ethylcarbamoyl)alkyl, 1-mercapto-ω-(N-benzylcarbamoyl)alkyl, 1-formyl-ω-ethoxycarbonylalkyl, 1-formyl-ω-benzyloxycarbonylalkyl, 1-formyl-(N-butylcarbamoyl)alkyl, 1-formyl-ω-(N-benzylcarbamoyl)alkyl and 1-formyl-ω-propionylalkyl groups, of which the alkyl groups have from 1 to 9 carbon atoms and are preferably the methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, iso-butyl, t-butyl, pentyl, isopentyl, hexyl, 2-methylbutyl, heptyl, octyl, 2-ethylhexyl or nonyl groups.

›DETAILED DESCRIPTION OF INVENTION · 5 of 16

Where X represents a group of formula --P(O)(R 5 )--OH, R 5 represents an alkyl group having a carboxy, protected carboxy, N-substituted carbamoyl, carbazoyl, N-substituted carbazoyl, C 2 -C 7 aliphatic carboxylic acyl or aromatic acyl or aromatic carboxylic acyl group. Examples of such groups represented by R 5 are given in relation to the similar groups which may be represented by R 4 . Examples of such groups which may be represented by X include the ω-carboxyalkylphosphinico, ω-methoxycarbonylalkylphosphinico, ω-ethoxycarbonylalkylphosphinico, ω-benzyloxycarbonylalkylphosphinico, ω-(N-butylcarbamoyl)alkylphosphinico, ω-[N-(2-methylbutyl)carbamoyl]alkylphosphinico, ω-[N-(1-hydroxy-2-methylbutyl)carbamoyl]alkylphosphinico, ω-[N-(1-benzyl-4-piperidyl)carbamoyl]alkylphosphinico, ω-(N 2 -butylcarbazoyl)alkylphosphinico, ω-[N 2 -(ω-phenylalkylcarbonyl)carbazoyl]alkylphosphinico and ω-[N 2 -(ω-benzoylalkylcarbonyl)carbazoyl]alkylphosphinico groups, in which the or each alkyl group has from 1 to 8 carbon atoms, and is preferably a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, isopentyl, hexyl, 2-methylbutyl, heptyl, octyl or 2-ethylhexyl group.

Where references are made hereinabove to substituted aryl groups, the substituents are preferably selected from the group consisting of: C 1 -C 4 alkyl groups, preferably methyl or ethyl groups; halogen atoms, preferably chlorine or bromine atoms; C 1 -C 4 alkoxy groups, preferably methoxy or ethoxy groups; hydroxy groups; nitro groups; amino groups; mercapto groups; and C 1 -C 4 alkylthio groups. Where references are made above to substituted heterocyclic groups, the substituents are preferably selected from the group consisting of: C 1 -C 4 alkyl groups, e.g. as exemplifiedd above; phenyl groups, which may optionally be substituted as for the aryl groups referred to above; benzyl groups which may optionally be substituted as for the aryl groups above; and halogen atoms.

Preferred compounds of the invention are those in which:

R 1 represents a group of formula R 13 --CH(NHR 12 )--, in which R 12 represents hydrogen, or a 2-(2-methoxyethoxy)ethoxycarbonyl, benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, t-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, 2-nitrophenylthio, 3-nitropyrid-2-ylthio, 4-phenylbutyryl or 3-(3-nitropyrid-2-yldithio)propionyl group; and R 13 represents a benzyl, benzyl having a substituent selected from the group consisting of C 1 -C 4 alkyl groups, amino groups, C 1 -C 4 alkoxy groups, hydroxy groups, halogen atoms, nitro groups, mercapto groups and C 1 -C 4 alkylthio groups, 1-naphthylmethyl, 2-naphthylmethyl, 3-indolylmethyl, 5-quinolylmethyl, 4-quinolylmethyl, 2-pyridylmethyl, 3-pyridylmethyl or 4-pyridylmethyl group;

R 2 represents a C 1 -C 10 alkyl group, a C 2 -C 5 alkenyl group, a C 2 -C 5 alkenyl group having at least one halogen substituent, a C 2 -C 4 alkynyl group, a C 3 -C 6 cycloalkyl group, a (C 3 -C 6 cycloalkyl)methyl group, a C 5 -C 8 cycloalkenyl group, a (C 5 -C 8 cycloalkenyl)methyl group, or a benzyl, 3-indolylmethyl, 2-thienylmethyl, 4-thiazolylmethyl, 2-thiazolylmethyl, 4-methyl-5-thiazolylmethyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 4-imidazolylmethyl, 2-pyrrolidinylmethyl, 1-(C 1 -C 4 alkyl)-2-pyrrolidinylmethyl, 1,3-thiazolidin-4-ylmethyl or 3-(C 1 -C 4 alkyl)-1,3-thiazolidin-4-ylmethyl group, or any such group wherein any C 1 -C 4 alkyl portion has at least one substituent selected from the group consisting of hydroxy groups, alkoxy groups, aralkyloxy groups, aliphatic carboxylic acyloxy groups, mercapto groups, alkylthio groups, alkylsulfinyl groups, alkylsulfonyl groups, amino groups, monoalkylamino groups, dialkylamino groups, aliphatic carboxylic acylamino groups, aromatic carboxylic acylamino groups, alkoxycarbonylamino groups, aralkyloxycarbonylamino groups, aliphatic carboxylic acyl groups, carboxy groups, alkoxycarbonyl groups, aryloxycarbonyl groups, aralkyloxycarbonyl groups, carbamoyl groups, ureido groups and guanidyl groups;

R 4 represents a protected carboxy group, a carbamoyl group, an N-substituted carbamoyl group, a carbazoyl group, an N-substituted carbazoyl group or an acyl group;

Y represents a hydroxy or mercapto group;

R 5 represents an alkyl group having a substituent selected from the group consisting of protected carboxy groups, N-substituted carbamoyl groups, carbazoyl groups, N-substituted carbazoyl groups, C 2 -C 7 aliphatic carboxylic acyl groups and aromatic carboxylic acyl groups; and

R 3 represents an isobutyl, sec-butyl, cyclopropylmethyl, cyclopentylmethyl or cyclohexylmethyl group.

A more preferred class of compounds of the invention are those in which:

R 1 represents a group of formula R 13 --CH(NHR 12 )-- in which:

R 12 represents a 2-(2-methoxyethoxy)ethoxycarbonyl, benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, t-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, 4-phenylbutyryl or 3-(3-nitropyrid-2-yldithio)propionyl group; and

R 13 represents a benzyl group, a benzyl group having at least one substituent selected from the group consisting of C 1 -C 4 alkyl groups and C 1 -C 4 alkoxy groups, a 1-naphthylmethyl group, a 3-indolylmethyl group, a 5-quinolylmethyl group, a 4-quinolylmethyl group, a 2-pyridylmethyl group, a 3-pyridylmethyl group or a 4-pyridylmethyl group;

R 2 represents a C 1 -C 10 alkyl group, an allyl group, a propargyl group, a cyclopropylmethyl group, a cyclopentylmethyl group, a cyclohexylmethyl group, a benzyl group, a 3-indolylmethyl group, a 2-thienylmethyl group, a 4-thiazolylmethyl group, a 2-thiazolylmethyl group, a 4-methyl-5-thiazolylmethyl group, a 2-pyridylmethyl group or a 4-imidazolylmethyl group;

R 4 represents a protected carboxy group, a carbamoyl group, an N-substituted carbamoyl group, a carbazoyl group, an N-substituted carbazoyl group or an acyl group;

Y represents a hydroxy or mercapto group;

R 5 represents an alkyl group having a substituent selected from the group consisting of protected carboxy, N-substituted carbamoyl, carbazoyl, N-substituted carbazoyl, C 2 -C 7 aliphatic carboxylic acyl and aromatic carboxylic acyl groups; and

›DETAILED DESCRIPTION OF INVENTION · 6 of 16

R 3 represents an isobutyl or sec-butyl group.

Specific examples of compounds of the invention are given in the following list; the numbers appended to the compounds in this list are, where appropriate, used hereafter to identify those compounds.

1. ethyl 4(S)-[N-(4-phenylbutyryl)-L-phenylalanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

2. p-bromophenacyl 4(S)-{N-[3-nitropyrid-2-yldithio)propionyl]-L-phenylalanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

3. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoic acid

4. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoic acid

5. ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

6. sec-butyl 4(S)-[N-acetyl-D-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

7. isobutyl 5(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-L-histidyl]amino-4(S)-hydroxy-7-methyloctanoate

8. ethyl 4(S)-[N-benzyloxycarbonyl-3-(2-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

9. methyl 3(S)-[N-benzyloxycarbonyl-3-(3-pyridyl)-L-alanyl-L-histidyl]amino-2(S)-hydroxy-5-methylhexanoate

10. ethyl 4(S)-[N-benzoyl-3-(5-quinolyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

11. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-5-methylheptanoic acid

12. ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-5-methylheptanoate

13. ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-L-histidyl]amino-3(S)-hydroxy-5-methylheptanoate

14. benzyl 3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-2(S)-hydroxy-5-methylhexanoate

15. benzyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

16. benzyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

17. benzyl 4(S)-[3-(1-naphthyl)-D-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

18. benzyl 5(S)-[t-butoxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-4(S)-hydroxy-7-methyloctanoate

19. benzyl 4(S)-[t-butoxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-5-methylheptanoate

20. benzyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-L-histidyl]amino-3(S)-hydroxy-5-methylheptanoate

21. phenyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

22. phenacyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

23. p-bromophenacyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

24. N-butyl-3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-2(S)-hydroxy-5-methylhexanamide

25. N-sec-butyl-3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-2(S)-hydroxy-5-methylhexanamide

26. N-benzyl-4(S)-[N-benzyloxycarbonyl-L-tyrosyl-L-histidyl]amino-3(S)-hydroxy-5-methylheptanamide

27. N-benzyl-3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-2(S)-hydroxy-5-methylhexanamide

28. N-benzyl-3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-L-histidyl]amino-2(S)-hydroxy-5-methylhexanamide

29. N-benzyl-3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-2(S)-hydroxy-4-methylhexanamide

30. 1-{3(S)-[N-benzoyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-2(S)-hydroxy-5-methylhexanoyl}-4-(m-tolyl)piperazine

31. 1-benzyl-4-{4(S)-[N-benzyloxycarbonyl-3-(1- naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamido}piperidine

32. 1-benzyl-4-{4(S)-[N-benzyloxycarbonyl-L-tryptophyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamido}piperidine

33. 4(S)-[N-acetyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methyl-N-(2-pyridylmethyl)heptanamide

34. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methyl-N-(4-pyridylmethyl)heptanamide

35. N-{4(S)-[N-benzyloxycarbonyl-L-tyrosyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

36. 1-{4(S)-[N- benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-4-phenylpiperidine

37. 1-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-4-benzylpiperazine

38. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoic acid hydrazide

39. N 1 -{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-N 2 -(4-phenylbutyryl)hydrazine

40. N 1 -{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-N 2 -(4-benzoylbutyryl)hydrazine

41. N 1 -butyl-N 2 -{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}hydrazine

42. N 1 -sec-butyl-N 2 -}4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}hydrazine

43. 1-propionyl-3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-2(S)-hydroxy-5-methylhexane

44. 1-benzoyl-3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-2(S)-hydroxy-5-methylhexane

45. benzyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-mercapto-6-methylheptanoate

46. N-benzyl-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-mercapto-6-methylheptanamide

47. benzyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-formyl-6-methylheptanoate

48. N-benzyl-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-formyl-6-methylheptanamide

49. 1-propionyl-4(S)-[N-benzyloxycarbonyl-L-phenylalanyl-L-histidyl]amino-3-formyl-6-methylheptane

50. methyl{1(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-L-histidyl]amino-3-methylbutylphosphinico}acetate

51. ethyl{1(S)-[N-benzyloxycarbonyl-3-(8-quinolyl)-D-alanyl-L-histidyl]amino-3-methylbutylphosphinico}acetate

52. ethyl 4(S)-[N-benzyloxycarbonyl-3-(5-quinolyl)-D-alanyl-L-histidyl]amino-6-methylheptanoate

›DETAILED DESCRIPTION OF INVENTION · 7 of 16

53. benzyl[1(RS)-{N-[N-t-butoxycarbonyl-3-(3-nitropyrid-2-yldithio)-L-alanyl]-L-phenylalanyl-L-histidyl}amino-2-methylbutylphosphinico]acetate

54. benzyl{1(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-L-histidyl]amino-3-methylbutylphosphinico}acetate

55. benzyl{1(S)-[3-(1-naphthyl)-D-alanyl-L-histidyl]amino-3-methylbutylphosphinico}acetate

56. benzyl{1(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-L-histidyl]amino-2-methylbutylphosphinico}acetate

57. N-benzyl-2-[1(RS)-{N-[3-(3-nitropyrid-2-yldithio)propionyl]-L-phenylalanyl-L-histidyl}amino-2-methylbutylphosphinico]acetamide

58. N-benzyl-2-{1(RS)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-L-histidyl]amino-3-methylbutylphosphinico}acetamide

59. N-benzyl-2-{1(RS)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-L-histidyl]amino-2-methylbutylphosphinico}acetamide

60. 4-[3-{1(RS)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3-methylbutylphosphinico}propionamido]-1-benzylpiperidine

61. methyl[1-{[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino}-3-methylbutylphosphinico]acetate

62. methyl 3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-2(S)-hydroxy-5-methylhexanoate

63. 1-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamido}-4-(3-trifluoromethylphenyl)piperazine

64. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-N-butyl-3(S)-hydroxy-6-methylheptanamide

65. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methyl-N-[S-(-)-2-methylbutyl]heptanamide

66. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-N-ethyl-3(S)-hydroxy-6-methylheptanamide

67. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

68. ethyl 4(S)-[N-(4-phenylbutyryl)-L-phenylalanyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

69. p-bromophenacyl 4(S)-{N-[3-(3-nitropyrid-2-yldithio)propinoyl]-L-phenylalanyl-D-histidyl}amino-3(S)-hydroxy-6-methylheptanoate

70. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanoic acid

71. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanoic acid

72. ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

73. sec-butyl 4(S)-[N-acetyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

74. isobutyl 5(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-D-histidyl]amino-4(S)-hydroxy-7-methyloctanoate

75. ethyl 4(S)-[N-benzyloxycarbonyl-3-(2-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

76. methyl 3(S)-[N-benzyloxycarbonyl-3-(3-pyridyl)-L-alanyl-D-histidyl]amino-2(S)-hydroxy-5-methylhexanoate

77. ethyl 4(S)-[N-benzoyl-3-(5-quinolyl)-L-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

78. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-hydroxy-5-methylheptanoic acid

79. ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-hydroxy-5-methylheptanoate

80. ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-D-histidyl]amino-3(S)-hydroxy-5-methylheptanoate

81. benzyl 3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-2(S)-hydroxy-5-methylhexanoate

82. benzyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

83. benzyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

84. benzyl 4(S)-[3-(1-naphthyl)-D-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

85. benzyl 5(S)-[t-butoxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-4(S)-hydroxy-7-methyloctanoate

86. benzyl 4(S)-[t-butoxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-hydroxy-5-methylheptanoate

87. benzyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-D-histidyl]amino-3(S)-hydroxy-5-methylheptanoate

88. phenyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

89. phenacyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

90. p-bromophenacyl 4(S)-]N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

91. N-butyl-3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-2(S)-hydroxy-5-methylhexanamide

92. N-sec-butyl-3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-2(S)-hydroxy-5-methylhexanamide

93. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methyl-N-(2-methylbutyl)heptanamide

94. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

95. N-benzyl-4(S)-[N-benzyloxycarbonyl-L-tyrosyl-D-histidyl]amino-3(S)-hydroxy-5-methylheptanamide

96. N-benzyl-3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-2(S)-hydroxy-5-methylhexanamide

97. N-benzyl-3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-D-histidyl]amino-2(S)-hydroxy-5-methylhexanamide

98. N-benzyl-3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-2(S)-hydroxy-4-methylhexanamide

99. 1-{3(S)-[N-benzoyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-2(S)-hydroxy-5-methylhexanamido}-4-(m-tolyl)piperazine

100. 4-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanamido}-1-benzylpiperidine

101. 4-{4(S)-[N-benzyloxycarbonyl-L-tyrptophyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanamido}-1-benzylpiperidine

102. 4(S)-[N-acetyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methyl-N-(2-pyridylmethyl)heptanamide

103. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methyl-N-(4-pyridylmethyl)heptanamide

104. N-{4(S)-[N-benzyloxycarbonyl-3-(4-chlorophenyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

105. 1-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-4-phenylpiperidine

106. 1-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-4-benzylpiperazine

›DETAILED DESCRIPTION OF INVENTION · 8 of 16

107. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanoic acid hydrazide

108. N 1 -{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-N 2 -(4-phenylbutyryl)hydrazine

109. N 1 -{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-N 2 -(4-benzoylbutyryl)hydrazine

110. N 1 -butyl-N 2 -{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}hydrazine

111. N 1 -sec-butyl-N 2 -{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}hydrazine

112. 1-propionyl-3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-2(S)-hydroxy-5-methylhexane

113. 1-benzoyl-3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-2(S)-hydroxy-5-methylhexane

114. benzyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-mercapto-6-methylheptanoate

115. N-benzyl-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-mercapto-6-methylheptanamide

116. benzyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-formyl-6-methylheptanoate

117. N-benzyl-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-formyl-6-methylheptanamide

118. 1-propionyl-4(S)-[N-benzyloxycarbonyl-L-phenylalanyl-D-histidyl]amino-3(S)-formyl-6-methylheptane

119. methyl {1(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-D-histidyl]amino-3-methylbutylphosphinico}acetate

120. ethyl {1(S)-[N-benzyloxycarbonyl-3-(8-quinolyl)-D-alanyl-D-histidyl]amino-3-methylbutylphosphinico}acetate

121. ethyl 4(S)-[N-benzyloxycarbonyl-3-(5-quinolyl)-D-alanyl-D-histidyl]amino-6-methylheptanoate

122. benzyl [1(RS)-{N-[N-t-butoxycarbonyl-3-(3-nitropyrid-2-yldithio)-L-alanyl]-L-phenylalanyl-D-histidyl}amino-2-methylbutylphosphinico]acetate

123. benzyl {1(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-D-histidyl]amino-3-methylbutylphosphinico}acetate

124. benzyl {1(S)-[3-(1-naphthyl)-D-alanyl-D-histidyl]amino-3-methylbutylphosphinico}acetate

125. benzyl {1(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-D-histidyl]amino-2-methylbutylphosphinico}acetate

126. N-benzyl-2-[1(RS)-{N-[3-(3-nitropyrid-2-yldithio)]-L-phenylalanyl-D-histidyl}amino-2-methylbutylphosphinico]acetamide

127. N-benzyl-2-{1(RS)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-D-histidyl]amino-3-methylbutylphosphinico}acetamide

128. N-benzyl-2-{1(RS)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-D-histidyl]amino-2-methylbutylphosphinico}acetamide

129. 4-[3-{1(RS)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3-methylbutylphosphinico}propionamido]-1-benzylpiperidine

130. ethyl 4(S)-[N-(4-phenylbutyryl)-L-phenylalanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

131. p-bromophenacyl 4(S)-{N-[3-(3-nitropyrid-2-yldithio)-propinoyl]-L-phenylalanyl-DL-histidyl}amino-3(S)-hydroxy-6-methylheptanoate

132. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanoic acid

133. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-DL-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanoic acid

134. ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

135. sec-butyl 4(S)-[N-acetyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

136. isobutyl 5(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-DL-histidyl]amino-4(S)-hydroxy-7-methyloctanoate

137. ethyl 4(S)-[N-benzyloxycarbonyl-3-(2-naphthyl)-L-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

138. methyl 3(S)-[N-benzyloxycarbonyl-3-(3-pyridyl)-L-alanyl-DL-histidyl]amino-2(S)-hydroxy-5-methylhexanoate

139. ethyl 4(S)-[N-benzoyl-3-(5-quinolyl)-L-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

140. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-3(S)-hydroxy-5-methylheptanoic acid

141. ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-3(S)-hydroxy-5-methylheptanoate

142. ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-DL-histidyl]amino-3(S)-hydroxy-5-methylheptanoate

143. benzyl 3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-2(S)-hydroxy-5-methylhexanoate

144. benzyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

145. benzyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

146. benzyl 4(S)-[3-(1-naphthyl)-D-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

147. benzyl 5(S)-[t-butoxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-4(S)-hydroxy-7-methyloctanoate

148. benzyl 4(S)-[t-butoxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-3(S)-hydroxy-5-methylheptanoate

149. benzyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-DL-histidyl]amino-3(S)-hydroxy-5-methylheptanoate

150. phenyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

151. phenacyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

152. p-bromophenacyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

153. N-butyl-3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-2(S)-hydroxy-5-methylhexanamide

154. N-sec-butyl-3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-2(S)-hydroxy-5-methylhexanamide

55. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

156. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

157. N-benzyl-4(S)-[N-benzyloxycarbonyl-L-tyrosyl-DL-histidyl]amino-3(S)-hydroxy-5-methylheptanamide

158. N-benzyl-3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-2(S)-hydroxy-5-methylhexanamide

159. N-benzyl-3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-DL-histidyl]amino-2(S)-hydroxy-5-methylhexanamide

›DETAILED DESCRIPTION OF INVENTION · 9 of 16

160. N-benzyl-3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-2(S)-hydroxy-4-methylhexanamide

161. 1-{3(S)-[N-benzoyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-2(S)-hydroxy-5-methylhexanamido}-4-(m-tolyl)piperazine

162. 4-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanamido}-1-benzylpiperidine

163. 4-{4(S)-[N-benzyloxycarbonyl-L-tryptophyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanamido}-1-benzylpiperidine

164. 4(S)-[N-acetyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methyl-N-(2-pyridylmethyl)heptanamide

165. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methyl-N-(4-pyridylmethyl)heptanamide

166. N-{4(S)-[N-benzyloxycarbonyl-3-(4-aminophenyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

167. 1{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-phenypiperidine

168. 1-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-4-benzylpiperazine

169. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanoic acid hydrazide

170. N 1 -{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-N 2 -(4-phenylbutyryl)hydrazine

171. N 1 -{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-N 2 -(4-benzoylbutyryl)hydrazine

172. N 1 -butyl-N 2 -{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}hydrazine

173. N 1 -sec-butyl-N 2 -{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-DL-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}hydrazine

174. 1-propionyl-3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-2(S)-hydroxy-5-methylhexane

175. 1-benzoyl-3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-2(S)-hydroxy-5-methylhexane

176. benzyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-3(S)-mercapto-6-methylheptanoate

177. N-benzyl-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-3(S)-mercapto-6-methylheptanamide

178. benzyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-3(S)-formyl-6-methylheptanoate

179. N-benzyl-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-3(S)-formyl-6-methylheptanamide

180. 1-propionyl-4(S)-[N-benzyloxycarbonyl-L-phenylalanyl-DL-histidyl]amino-3(S)-formyl-6-methylheptane

181. methyl {1(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-DL-histidyl]amino-3-methylbutylphosphinico}acetate

182. ethyl {1(S)-[N-benzyloxycarbonyl-3-(8-quinolyl)-D-alanyl-DL-histidyl]amino-3-methylbutylphosphinico}acetate

183. ethyl 4(S)-[N-benzyloxycarbonyl-3-(5-quinolyl)-D-alanyl-DL-histidyl]amino-6-methylheptanoate

184. benzyl [1(RS)-{N-[N-t-butoxycarbonyl-S-(3-nitropyrid-2-ylthio)-L-cysteinyl]-L-phenylalanyl-DL-histidyl}amino-2-methylbutylphosphinico]acetate

185. benzyl {1(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-DL-histidyl]amino-3-methylbutylphosphinico}acetate

186. benzyl {1(S)-[3-(1-naphthyl)-D-alanyl-DL-histidyl]amino-3-methylbutylphospinico}acetate

187. benzyl {1(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-DL-histidyl]amino-2-methylbutylphosphinico}acetate

158. N-benzyl-2-[1(RS)-{N-[3-(3-nitropyrid-2-yldithio)-L-phenylalanyl-DL-histidyl}amino-2-methylbutylphosphinico]acetamide

189. N-benzyl-2-{1(RS)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-DL-histidyl]amino-3-methylbutylphosphinico}acetamide

190. N-benzyl-2-{1(RS)-[N-benzyloxycarbonyl-3-(1-naphthyl)-D-alanyl-DL-histidyl]amino-2-methylbutylphosphinico}acetamide

191. 4-[3-{1(RS)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-DL-histidyl]amino-3-methylbutylphosphinico}propionamido]-1-benzylpiperidine

192. ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanoate

193. 2-methylbutyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanoate

194. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanamide

195. N-sec-butyl-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanamide

196. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanamide

197. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

198. 4-{4(S)-[N-benzyloxycarbonyl-3-(1-napthyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanamido}-1-benzylpiperidine

199. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methyl-N-[2-(2-pyridyl)ethyl]heptanamide

200. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methyl-N-(2-morpholinoethyl)heptanamide

201. N-ethyl-N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanamide

202. N 1 -(4-benzoylbutyryl)-N 2 -{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanoyl}hydrazine

203. ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanoate

204. 2-methylbutyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanoate

205. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanamide

206. N-sec-butyl-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanamide

207. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanamide

208. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

209. 4-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanamido}-1-benzylpiperidine

210. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methyl-N-[2-(2-pyridyl)ethyl]heptanamide

›DETAILED DESCRIPTION OF INVENTION · 10 of 16

211. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methyl-N-(2-morpholinoethyl)heptanamide

212. N-ethyl-N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanamide

213. N 1 -(4-benzoylbutyryl)-N 2 -{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanoyl}hydrazine

214. ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-thienyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoate

215. 2-methylbutyl 4-(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-thienyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoate

216. N-sec-butyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-thienyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

217. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-thienyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

218. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-thienyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

219. 4-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-thienyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamido}-benzylpiperidine

220. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-thienyl)-DL-alanyl]amino-3(S)-hydroxy-6-methyl-N-[2-(2-pyridyl)ethyl]heptanamide

221. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-thienyl)-DL-alanyl]amino-3(S)-hydroxy-6-methyl-N-(2-morpholinoethyl)heptanamide

222. N-ethyl-N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-thienyl)-DL-alanyl]amino-3-(S)-hydroxy-6-methylheptanamide

223. N 1 -(4-benzoylbutyryl)-N 2 -{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-thienyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}hydrazine

224. ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-2-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoate

225. 2-methylbutyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-2-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoate

226. N-sec-butyl-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-2-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

227. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-2-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

228. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-thiazolyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

229. 4-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-2-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamido}-1-benzylpiperidine

230. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-2-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methyl-N-[2-(2-pyridyl)ethyl]heptanamide

231. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl]-3-(1,3-thiazol-2-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methyl-N-(2-morpholinoethyl)heptanamide

232. N-ethyl-N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-2-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

233. N 1 -(4-benzoylbutyryl)-N 2 -{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-2-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}hydrazine

234. ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoate

235. 2-methylbutyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoate

236. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

237. N-sec-butyl-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

238. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

239. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

240. 4-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamido}-1-benzylpiperidine

241. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-thiazolyl)-DL-alanyl]amino-3(S)-hydroxy-6-methyl-N-[2-(2-pyridyl)ethyl]heptanamide

242. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-thiazolyl)-DL-alanyl]amino-3(S)-hydroxy-6-methyl-N-(2-morpholinoethyl)heptanamide

243. N-(2-phenylpropyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-thiazolyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

244. N 1 -(4-benzoylbutyryl)-N 2 -{4(S)-[N-benzyloxy-carbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}hydrazine

245. ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-methyl-1,3-thiazol-5-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoate

246. 2-methylbutyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-methyl-1,3-thiazol-5-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoate

247. N-sec-butyl-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-methyl-1,3-thiazol-5-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

248. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-methyl-1,3-thiazol-5-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

249. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-methyl-1,3-thiazol-5-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

250. 4-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-methyl-1,3-thiazol-5-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamido}-1-benzylpiperidine

251. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-methyl-1,3-thiazol-5-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methyl-N-[2-(2-pyridyl)ethyl]heptanamide

252. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-methyl-1,3-thiazol-5-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methyl-N-(2-morpholinoethyl)heptanamide

253. N-ethyl-N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-methyl-1,3-thiazol-5-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

›DETAILED DESCRIPTION OF INVENTION · 11 of 16

254. N 1 -(4-benzoylbutyryl)-N 2 -{4(S)-[N-benzyloxy-carbonyl-3-(1-naphthyl)-L-alanyl-3-(4-methyl-1,3-thiazol-5-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}hydrazine

255. ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoate

256. 2-methylbutyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoate

257. N-sec-butyl-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

258. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

259. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

260. 4-{4(S)-N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyridyl)-DL-alanyl]amino-2(S)-hydroxy-6-methylheptanamido}-1-benzylpiperidine

261. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methyl-N-[2-(2-pyridyl)ethyl]heptanamide

262. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methyl-N-(2-morpholinoethyl)heptanamide

263. N-(2-phenylpropyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyridyl)-DL-alanyl]amino-3-(S)-hydroxy-6-methylheptanamide

264. N 1 -(4-benzoylbutyryl)-N 2 -{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}hydrazine

265. ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(3-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoate

266. 2-methylbutyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(3-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoate

267. N-sec-butyl-4-(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(3-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

268. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(3-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

269. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(3-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

270. 4-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(3-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamido}-1-benzylpiperidine

271. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(3-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methyl-N-[2-(2-pyridyl)ethyl]heptanamide

272. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(3-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methyl-N-(2-morpholinoethyl)heptanamide

273. N-ethyl-N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(3-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

274. N 1 -(4-benzoylbutyryl)-N 2 -{4(S)-benzyloxy-carbonyl-3-(1-naphthyl)-L-alanyl-3-(3-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}hydrazine

275. ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoate

276. 2-methylbutyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoate

277. N-sec-butyl-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

278. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

279. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

280. 4-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamido}-1-benzylpiperidine

281. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methyl-N-[2-(2-pyridyl)ethyl]heptanamide

282. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methyl-N-(2-morpholinoethyl)heptanamide

283. N-ethyl-N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

284. N 1 -(4-benzoylbutyryl)-N 2 -{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}hydrazine

285. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-5-methylheptanamide

286. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-5-methylheptanoyl}-L-isoleucinol

287. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-5-methylheptanamide

288. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-5-methylheptanoyl}-L-isoleucinol

289. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-thienyl)-DL-alanyl]amino-3(S)-hydroxy-5-methylheptanamide

290. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-thienyl)-DL-alanyl]amino-3(S)-hydroxy-5-methylheptanoyl}-L-isoleucinol

291. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-thiazolyl)-DL-alanyl]amino-3(S)-hydroxy-5-methylheptanamide

292. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-thiazolyl)-DL-alanyl]amino-3(S)-hydroxy-5-methylheptanoyl}-L-isoleucinol

293. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-thiazolyl)-DL-alanyl]amino-3(S)-hydroxy-5-methylheptanamide

294. N-{4(S)-N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-thiazolyl)-DL-alanyl]amino-3(S)-hydroxy-5-methylheptanoyl}-L-isoleucinol

295. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-methyl-1,3-thiazol-5-yl)-DL-alanyl]amino-3(S)-hydroxy-5-methylheptanamide

296. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-methyl-1,3-thiazol-5-yl)-DL-alanyl]amino-3(S)-hydroxy-5-methylheptanoyl}-L-isoleucinol

297. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-5-methylheptanamide

298. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-5-methylheptanoyl}-L-isoleucinol

›DETAILED DESCRIPTION OF INVENTION · 12 of 16

299. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(3-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-5-methylheptanamide

300. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(3-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-5-methylheptanoyl}-L-isoleucinol

301. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-5-methylheptanamide

302. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-5-methylheptanoyl}-L-isoleucinol

303. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-cyclopentyl-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

304. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-cyclopentyl-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

305. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-phenylalanyl]amino-3(S)-hydroxy-6-methylheptanamide

306. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-phenylalanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

307. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1-naphthyl)-L-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

308. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1-naphthyl)-L-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

309. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-tryptophyl]amino-3(S)-hydroxy-6-methylheptanamide

310. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-tryptophyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

311. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3(1-naphthyl)-L-alanyl-L-valyl]amino-3(S)-hydroxy-6-methylheptanamide

312. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-valyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

313. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-isoleucyl]amino-3(S)-hydroxy-6-methylheptanamide

314. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-isoleucyl]amino-3(S)-hydroxy-6-methylheptanyl}-L-isoleucinol

315. N-(2-methylbutyl)-1-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-norvalyl]amino-3(S)-hydroxy-6-methylheptanamide}

316. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-norvalyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

317. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyrrolidinyl)-L-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

318. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyrrolidinyl)-L-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

319. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1-methyl-2-pyrrolidinyl)-L-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

320. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1-methyl-2-pyrrolidinyl)-L-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

321. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazolidin-4-yl)-L-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

322. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazolidin-4-yl)-L-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

323. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(3-methyl-1,3-thiazolidin-4-yl)-L-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

324. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(3-methyl-1,3-thiazolidin-4-yl)-L-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

325. N-(2-methylbutyl)-4(S)-{2(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl]aminoheptanoyl}amino-3(S)-hydroxy-6-methylheptanamide

326. N-[4(S)-{2(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl]aminoheptanoyl}amino-3(S)-hydroxy-6-methylheptanoyl]-L-isoleucinol

327. N-(2-methylbutyl)-4(S)-{2(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl]aminononanoyl}amino-3(S)-hydroxy-6-methylheptanamide

328. N-[4(S)-{2(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl]aminononanoyl}amino-3(S)-hydroxy-6-methylheptanoyl]-L-isoleucinol

329. N-(2-methylbutyl)-4(S)-{2(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl]aminododecanoyl}amino-3(S)-hydroxy-6-methylheptanamide

330. N-[4(S)-{2(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl]aminododecanoyl}amino-3(S)-hydroxy-6-methylheptanoyl]-L-isoleucinol

331. N-(2-methylbutyl)-4(S)-{2(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl]aminopent-4-enoyl}amino-3(S)-hydroxy-6-methylheptanamide

332. N-[4(S)-{2(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl]aminopent-4-enoyl}amino-3(S)-hydroxy-6-methylheptanoyl]-L-isoleucinol

333. N-(2-methylbutyl)-4(S)-{2(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl]aminopent-4-ynoyl}amino-3(S)-hydroxy-6-methylheptanamide

334. N-[4(S)-{2(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl]aminopent-4-ynoyl}amino-3(S)-hydroxy-6-methylheptanoyl]-L-isoleucinol

335. N-(2-methylbutyl)-4(S)-{N-[2(2-methoxyethoxy)ethoxycarbonyl]-3-(1-naphthyl)-L-alanyl-L-histidyl}amino-3(S)-hydroxy-6-methylheptanamide

336. N-[4(S)-{N-[2-(2-methoxyethoxy)ethoxycarbonyl]-3-(1-naphthyl)-L-alanylhistidyl}amino-3(S)-hydroxy-6-methylheptanoyl]-L-isoleucinol

337. N-(2-methylbutyl)-4(S)-{N-[2-(2-methoxyethoxy)ethoxycarbonyl]-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl}amino-3(S)-hydroxy-6-methylheptanamide

338. N-[4(S)-{N-[2-(2-methoxyethoxy)ethoxycarbonyl]-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl}amino-3(S)-hydroxy-6-methylheptanoyl]-L-isoleucinol

339. N-(2-methylbutyl)-4(S)-{N-[2-(2-methoxyethoxy)ethoxycarbonyl]-3-(1-naphthyl)-L-alanyl-L-norleucyl}amino-3(S)-hydroxy-6-methylheptanamide

340. N-[4(S)-{N-[2-(2-methoxyethoxy)ethoxycarbonyl]-3-(1-naphthyl)-L-alanyl-L-norleucyl}amino-3(S)-hydroxy-6-methylheptanoyl]-L-isoleucinol

341. N-(2-methylbutyl)-4(S)-{N-[2-(2-methoxyethoxy)ethoxycarbonyl]-3-(1-naphthyl)-L-alanyl-L-leucyl}amino-3(S)-hydroxy-6-methylheptanamide

342. N-[4(S)-{N-[2-(2-methoxyethoxy)ethoxycarbonyl]-3-(1-naphthyl)-L-alanyl-L-leucyl}amino-3(S)-hydroxy-6-methylheptanoyl]-L-isoleucinol

343. N-(2-methylbutyl)-4(S)-[N-(4-methoxybenzyloxycarbonyl)-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

›DETAILED DESCRIPTION OF INVENTION · 13 of 16

344. N-{4(S)-[N-(4-methoxybenzyloxycarbonyl)-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

345. N-(2-methylbutyl)-4(S)-[N-(4-methoxybenzyloxycarbonyl)-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

346. N-{4(S)-[N-(4-methoxybenzyloxycarbonyl)-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl]-L-isoleucinol

347. N-(2-methylbutyl)-4(S)-[N-(4-methoxybenzyloxycarbonyl)-3-(1-naphthyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanamide

348. N-{4(S)-[N-(4-methoxybenzyloxycarbonyl)-3-(1-naphthyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

349. N-(2-methylbutyl)-4(S)-[N-(4-methoxybenzyloxycarbonyl)-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanamide

350. N-{4(S)-[N-(4-methoxybenzyloxycarbonyl)-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

351. N-(2-methylbutyl)-4(S)-[N-(t-butoxycarbonyl)-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

352. N-{4(S)-[N-(t-butoxycarbonyl)-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

353. N-(2-methylbutyl)-4(S)-[N-(t-butoxycarbonyl)-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

354. N-{4(S)-[N-(t-butoxycarbonyl)-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamido}-L-isoleucinol

355. N-(2-methylbutyl)-4(S)-[N-(t-butoxycarbonyl)-3-(1-naphthyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanamide

356. N-{4(S)-[N-(t-butoxycarbonyl)-3-(1-naphthyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

357. N-(2-methylbutyl)-4(S)-[N-(t-butoxycarbonyl)-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanamide

358. N-{4(S)-[N-(t-butoxycarbonyl)-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

359. N-(2-methylbutyl)-4(S)-[N-9-fluorenylmethoxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

360. N-{4(S)-[N-9-fluorenylmethoxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

361. N-(2-methylbutyl)-4(S)-[N-9-fluorenylmethoxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]-amino-3(S)-hydroxy-6-methylheptanamide

362. N-{4(S)-[N-9-fluorenylmethoxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

363. N-(2-methylbutyl)-4(S)-[N-9-fluorenylmethoxycarbonyl-3-(1-naphthyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanamide

364. N-{4(S)-[N-9-fluorenylmethoxycarbonyl-3-(1-naphthyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

365. N-(2-methylbutyl)-4(S)-[N-fluoren-9-ylmethoxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanamide

366. N-{4(S)-[N-fluoren-9-ylmethoxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

367. N-(2-methylbutyl)-4(S)-{N-[3-(3-nitropyrid-2-yldithio)propionyl]-3-(1-naphthyl)-L-alanyl-L-histidyl}amino-3(S)-hydroxy-6-methylheptanamide

368. N-[4(S)-{N-[3-(3-nitropyrid-2-yldithio)propionyl]-3-(1-naphthyl)-L-alanyl-L-histidyl}amino-3(S)-hydroxy-6-methylheptanoyl]-L-isoleucinol

369. N-(2-methylbutyl)-4(S)-{N-[3-(3-nitropyrid-2-yldithio)propionyl]-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl}amino-3(S)-hydroxy-6-methylheptanamide

370. N-[4(S)-{N-[3-(3-nitropyrid-2-yldithio)propionyl]-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl}amino-3(S)-hydroxy-6-methylheptanoyl]-L-isoleucinol

371. N-(2-methylbutyl)-4(S)-{N-[3-(3-nitropyrid-2-yldithio)propionyl]-3-(1-naphthyl)-L-alanyl-L-norleucyl}amino-3(S)-hydroxy-6-methylheptanamide

372. N-[4(S)-{N-[3-(3-nitropyrid-2-yldithio)propionyl]-3-(1-naphthyl)-L-alanyl-L-norleucyl}amino-3(S)-hydroxy-6-methylheptanoyl]-L-isoleucinol

373. N-(2-methylbutyl)-4(S)-{N-[3-(3-nitropyrid-2-yldithio)propionyl]-3-(1-naphthyl)-L-alanyl-L-leucyl}amino-3(S)-hydroxy-6-methylheptanamide

374. N-[4(S)-{N-[3-(3-nitropyrid-2-yldithio)propionyl]-3-(1-naphthyl)-L-alanyl-L-leucyl}amino-3(S)-hydroxy-6-methylheptanoyl]-L-isoleucinol

375. N-(2-methylbutyl)-4(S)-[N-(4-phenylbutyryl)-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

376. N-{4(S)-[N-(4-phenylbutyryl)-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

377. N-(2-methylbutyl)-4(S)-[N-(4-phenylbutyryl)-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

378. N-{4(S)-[N-4-phenylbutyryl)-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-analyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

379. N-(2-methylbutyl)-4(S)-[N-(4-phenylbutyryl)-3-(1-naphthyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanamide

380. N-{4(S)-[N-(4-phenylbutyryl)-3-(1-naphthyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

381. N-(2-methylbutyl)-4(S)-[N-(4-phenylbutyryl)-3-(1-naphthyl)-L-alanyl-L-leucyl}amino-3(S)-hydroxy-6-methylheptanamide

382. N-{4(S)-[N-(4-phenylbutyryl)-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

383. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-L-phenylalanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

384. N-{4(S)-[N-benzyloxycarbonyl-L-phenylalanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

385. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-L-phenylalanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

386. N-{4(S)-[N-benzyloxycarbonyl-L-phenylalanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

387. N-(2-methylbutyl)-4(S)-(N-benzyloxycarbonyl-L-phenylalanyl-L-norleucyl)amino-3(S)-hydroxy-6-methylheptanamide

388. N-4(S)-(N-benzyloxycarbonyl-L-phenylalanyl-L-norleucyl)amino-3(S)-hydroxy-6-methylheptanoyl]-L-isoleucinol

389. N-(2-methylbutyl)-4(S)-(N-benzyloxycarbonyl-L-phenylalanyl-L-leucyl)amino-3(S)-hydroxy-6-methylheptanamide

›DETAILED DESCRIPTION OF INVENTION · 14 of 16

390. N-[4(S)-(N-benzyloxycarbonyl-L-phenylalanyl-L-leucyl)amino-3(S)-hydroxy-6-methylheptanoyl]-L-isoleucinol

391. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(2,3,4,5,6-pentamethylphenyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

392. N-{4(S)-[N-benzyloxycarbonyl-3-(2,3,4,5,6-pentamethylphenyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

393. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(2,3,4,5,6-pentamethylphenyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

394. N-{4(S)-[N-benzyloxycarbonyl-3-(2,3,4,5,6-pentamethylphenyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

395. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(2,3,4,5,6-pentamethylphenyl)-L-alanyl-L-norleucyl]-amino-3(S)-hydroxy-6-methylheptanamide

396. N-{4(S)-[N-benzyloxycarbonyl-3-(2,3,4,5,6-pentamethylphenyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

397. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(2,3,4,5,6-pentamethylphenyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanamide

398. N-{4(S)-[N-benzyloxycarbonyl-3-(2,3,4,5,6-pentamethylphenyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

399. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-L-tryptophyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

400. N-{4(S)-[N-benzyloxycarbonyl-L-tryptophyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

401. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-L-tryptophyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

402. N-{4(S)-[N-benzyloxycarbonyl-L-tryptophyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

403. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-L-tryptophyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanamide

404. N-{4(S)-[N-benzyloxycarbonyl-L-tryptophyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

405. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-L-tryptophyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanamide

406. N-{4(S)-[N-benzyloxycarbonyl-L-tryptophyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

407. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(4-quinolyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

408. N-{4(S)-[N-benzyloxycarbonyl-3-(4-quinolyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

409. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(4-quinolyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

410. N-{4(S)-[N-benzyloxycarbonyl-3-(4-quinolyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

411. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(4-quinolyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanamide

412. N-{4(S)-[N-benzyloxycarbonyl-3-(4-quinolyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

413. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(4-quinolyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanamide

414. N-{4(S)-[N-benzyloxycarbonyl-3-(4-quinolyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

415. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(5-quinolyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

416. N-{4(S)-[N-benzyloxycarbonyl-3-(5-quinolyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

417. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(5-quinolyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

418. N-{4(S)-[N-benzyloxycarbonyl-3-(5-quinolyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

419. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(5-quinolyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanamide

420. N-{4(S)-[N-benzyloxycarbonyl-3-(5-quinolyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

421. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(5-quinolyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanamide

422. N-{4(S)-[N-benzyloxycarbonyl-3-(5-quinolyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

423. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(2-pyridyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

424. N-{4(S)-[N-benzyloxycarbonyl-3-(2-pyridyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

425. N-(2-methylbutyl)-4(S)-[N-[benzyloxycarbonyl-3-(2-pyridyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

426. N-{4(S)-[N-benzyloxycarbonyl-3-(2-pyridyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

427. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(2-pyridyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanamide

428. N-{4(S)-[N-benzyloxycarbonyl-3-(2-pyridyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

429. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(2-pyridyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanamide

430. N-{4(S)-[N-benzyloxycarbonyl-3-(2-pyridyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

431. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(3-pyridyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

432. N-{4(S)-[N-benzyloxycarbonyl-3-(3-pyridyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

433. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(3-pyridyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

434. N-{4(S)-[N-benzyloxycarbonyl-3-(3-pyridyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

435. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(3-pyridyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanamide

436. N-{4(S)-[N-benzyloxycarbonyl-3-(3-pyridyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

437. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(3-pyridyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanamide

›DETAILED DESCRIPTION OF INVENTION · 15 of 16

438. N-{4(S)-[N-benzyloxycarbonyl-3-(3-pyridyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

439. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(4-pyridyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

440. N-{4(S)-[N-benzyloxycarbonyl-3-(4-pyridyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

441. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(3-pyridyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide

442. N-{4(S)-[N-benzyloxycarbonyl-3-(4-pyridyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

443. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(4-pyridyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanamide

444. N-{4(S)-[N-benzyloxycarbonyl-3-(4-pyridyl)-L-alanyl-L-norleucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

445. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(4-pyridyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanamide

446. N-{4(S)-[N-benzyloxycarbonyl-3-(4-pyridyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

447. N-{4(S)-[N-benzyloxycarbonyl-3-(4-nitrophenyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

448. 2-methylbutyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

449. N-{4(S)-[2(S)-N-benzyloxycarbonylamino-4-phenylbutyryl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

450. N-{4(S)-[α-benzyloxycarbonyl-L-phenylglycyl)-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

451. N-[α-{1(S)-[2(S)-(N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl)aminobut-3-enoyl]amino-3-methylbutylphosphinico}acetyl]-L-isoleucinol

452. N-isopropyl-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

453. N-sec-butyl-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

454. N-isobutyl-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

455. ethyl 5(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-4(S)-hydroxy-7-methyloctanoate

456. ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-6-methylheptanoate

457. 1-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-leucinol

458. 2-[2-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamido}ethyl]-1-methylpyrrolidine

459. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methyl-N-(2-morpholinoethyl)heptanamide

460. N-phenethyl-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

461. 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methyl-N-[2-(2-pyridyl)ethyl]heptanamide

462. 4-[2-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamido}ethyl]-1-benzylpiperidine

463. N-cyclohexyl-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

464. ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-mercapto-6-methylheptanoate

465. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-mercapto-6-methylheptanamide

466. N-ethyl-N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

467. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-mercapto-6-methylheptanoyl}-L-isoleucinol

468. N-(7,7-dimethylnorpinanylmethyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

469. ethyl 6-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamido}-2-t-butoxycarbonylaminohexanoate

470. ethyl 2-amino-6-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamido}hexanoate

471. 2-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamido}-3-benzyloxybutanol

472. 2-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamido}butan-1,3-diol

473. ethyl 2-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamido}-4-phenylbutyrate

474. N-(2,3-dihydroxypropyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

475. 2-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamido}-4-octadecen-1,3-diol

476. 1-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-4-[3-(3,4,5-trimethoxyphenyl)propenoyl]piperazine

477. 1-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-4-(3,4-methylenedioxybenzyl)piperazine

478. t-butyl 1-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamido}pyrrolidine-2-carboxylate

479. N-(2-phenylpropyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

480. N-cyclohexylmethyl-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

481. 1-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-4-benzylpiperazine

482. 3-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamido}-6-methylheptan-1,3-diol

483. N-(1-ethyl-2-pyrrolidinylmethyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

484. α-{1(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3-methylbutylphosphinico}-acetic acid

485. N 1 -{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-N 2 -(4-chlorobutyryl)hydrazine

›DETAILED DESCRIPTION OF INVENTION · 16 of 16

486. N-(2-methylbutyl)-α-{1(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3-methylbutylphosphinico}acetamide

487. N 1 -{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-N 2 -sec-butylhydrazine

488. N-[α-{1(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3-methylbutylphosphinico}acetyl]-L-isoleucinol

489. N-[α-{1(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3-methylbutylphosphinico}acetyl]-L-isoleucinol

490. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-5-methylheptanamide

491. N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-5-methylheptanoyl}-L-isoleucinol

492. N 1 -{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-5-methylheptanoyl}-N 2 -(4-chlorobutyryl)hydrazine

493. N-{4(S)-[2(S)-{N-[2-(2-methoxyethoxy)ethoxycarbonyl]-3-(1-naphthyl)-L-alanyl}aminoheptanoyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

494. N-(2-methylbutyl)-4(S)-[2(S)-{N-[2-(2-methoxyethoxy)ethoxycarbonyl]-3-(1-naphthyl)-L-alanyl}aminoheptanoyl]amino-3(S)-hydroxy-6-methylheptanamide

495. methyl 3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-norleucyl]amino-2(S)-hydroxy-5-methylhexanoate

496. N-{4(S)-[2(S)-{N-[2-(2-methoxyethoxy)ethoxycarbonyl]-3-(1-naphthyl)-L-alanyl}aminopent-4-enoyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

497. N-(2-methylbutyl)-4(S)-[2(S)-{N-[2-(2-methoxyethoxy)ethoxycarbonyl]-3-(1-naphthyl)-L-alanyl}aminopent-4-enoyl]amino-3(S)-hydroxy-6-methylheptanamide

498. N-{4(S)-[2(S)-{N-[2-(2-methoxyethoxy)ethoxycarbonyl]-3-(1-naphthyl)-L-alanyl}aminopent-4-ynoyl]amino-3(S)-hyroxy-6-methylheptanoyl}-L-isoleucinol

499. N-(2-methylbutyl)-4(S)-[2(S)-{N-[2-(2-methoxyethoxy)ethoxycarbonyl]-3-(1-naphthyl)-L-alanyl}aminopent-4-ynoyl]amino-3(S)-hydroxy-6-methylheptanamide

500. N-(2-methylbutyl)-4(S)-[3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

501. N-{4(S)-[3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

502. N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(2-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide

503. N-{4(S)-[N-benzyloxycarbonyl-3-(2-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

504. N-[α-{1(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3-methylbutylphosphinico}acetyl]-L-isoleucinol

505. N-[α-{1(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyridyl)-DL-alanyl]amino-3-methylbutylphosphinico}acetyl]-L-isoleucinol

Of the compounds listed above, the preferred compounds are Compounds No. 65, 66, 67, 192, 195, 196, 197, 200, 203, 206, 207, 208, 211, 216, 217, 218, 234, 237, 238, 239, 242, 258, 259, 285, 286, 287, 288, 289, 290, 293, 294, 297, 298, 303, 304, 305, 306, 309, 310, 311, 312, 313, 314, 315, 316, 325, 326, 327, 328-382 inclusive, 452, 453, 454, 457, 458, 459, 482, 483, 490-494 inclusive and 496-499 inclusive, more preferably Compounds No. 65, 66, 67, 207, 208, 218, 238, 239, 242, 259, 335, 453, 454, 457, 458, 482 and 483.

The compounds of the invention include pharmaceutically acceptable salts of the compounds of formula (I). Since the compounds of formula (I) contain basic nitrogen atoms and may, depending upon the nature of the group represented by X, also contain acidic groups, such salts may be acid addition salts or salts with bases. The nature of the salt is not critical, provided that it is pharmaceutically acceptable, and acids and bases which may be employed to form such salts are, of course, well known to those skilled in this art. Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulfuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid. Other salts include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases, such as dicyclohexylamine. All of these salts may be prepared by conventional means from the corresponding compound of formula (I), for example simply by reacting the appropriate acid or base with the compound of formula (I).

The compounds of the present invention can be prepared by conventional processes.

For example, the compounds of the invention, especially alcohol products [in which the substituent Y in the desired compound (I) represents a hydroxy group], thioalcohol products [in which Y represents a mercapto group] or phosphonic acid products [in which X represents the group --P(O)(R 5 )--OH], can be prepared by any conventional process used in peptide synthesis (for example, the azide process, the active ester process, the mixed acid anhydride process, the carbodiimide process or the condensation process using an oxidation-reduction system) by reacting a carboxylic acid having the general formula (II):

R.sup.1 CO--NH--CH(R.sup.2)--COOH (II)

(wherein R 1 and R 2 have the same meaning as above), or a reactive derivative thereof (such as a halide, anhydride, mixed anhydride, azide, active ester, active amide or carbodiimide), and an amino compound having the general formula (III):

H.sub.2 N--CH(R.sup.3)--X'

[in which: X' represents a group of formula --P(O)(OH)--R 5 or --CH(Y')--A-R 4 , in which A, R 4 and R 5 are as defined above and Y' represents a hydroxy or mercapto group; and R 3 is as defined above, but is preferably an isobutyl or sec-butyl group].

Compounds of the invention can also be prepared by acyl exchange reactions involving any of the groups R 1 CO--, NH 2 CH(R 2 )CO-- or NH 2 CH(R 3 )CO--, most conveniently R 1 CO-- or NH 2 CH(R 3 )CO--, by conventional means or by other conventional transformation reactions, for example conversion of a carboxy or protected carboxy group included within the group represented by X to, for example, a carbamoyl, N-substituted carbamoyl, carbazoyl or N-substituted carbazoyl group.

›INHIBITION OF RENIN ACTIVITY

The ability of various compounds of the invention to inhibit the activity of renin was determined according to the following method, which follows essentially the procedure of Kokubu et al. [Hypertension, 5, 191-197 (1983)].

Specifically, each test compound was dissolved in 60% v/v aqueous ethanol. Human renin activity in the presence and absence of each compound was measured using sheep angiotensinogen. The total volume of 1 ml of assay mixture contained 0.1 mole/liter phosphate buffer (pH 7.3), human renin (equivalent to 0.5 ng angiotensin I per ml per minute), sheep angiotensinogen (equivalent to 200 ng angiotensin I), the indicated concentration of the test compound, 6% ethanol and angiotensinase inhibitors (10 mmole/liter sodium ethylenediaminetetraacetate and 3.4 mmole/liter 8-hydroxyquinoline). The mixture was allowed to react for 10 minutes at 37° C., and then the reaction was stopped by placing the reaction tube in a boiling water bath for 5 minutes. The mixture was then centrifuged and the supernatant (0.05-0.1 ml) was used to assay remaining angiotensin I.

An identical experiment was carried out, as a control, except that the test compound was omitted. From the values obtained were calculated the % inhibition of renin activity achieved by each test compound. The results are shown in the following Table, in which the compounds of the invention are identified by the numbers assigned to them in the foregoing list. The values given are the mean of 3 or 4 experiments.

›TABLE

______________________________________

Compound Concentration

% Inhibition

No. of test cpd.

(human renin)

______________________________________

3 1 × 10.sup.-5 M

5 1 × 10.sup.-5 M

36 1 × 10.sup.-5 M

38 1 × 10.sup.-5 M

39 1 × 10.sup.-5 M

62 1 × 10.sup.-5 M

64 1 × 10.sup.-5 M

65 1 × 10.sup.-5 M

66 1 × 10.sup.-5 M

67 1 × 10.sup.-5 M

93 1 × 10.sup.-5 M

207 1 × 10.sup.-6 M

98.4

208 1 × 10.sup.-6 M

99.1

238 1 × 10.sup.-6 M

98.2

______________________________________

As can be seen from the above Table, the compounds of the invention have a substantial inhibitory effect on the activity of human renin and are thus useful for the diagnosis and therapy of renin/angiotensin-induced hypertension in humans and other animals.

The route of administration may be oral or parenteral and the compound of the invention may be formulated accordingly, normally with a pharmaceutically acceptable carrier or diluent as, for example, a tablet, capsule, granule, powder or syrup for oral administration or as an injection or suppository for parenteral administration. The dosage will vary depending upon the age, symptoms and body weight of the patient as well as upon the desired end result, but normally we would anticipate a dose of from 0.01 mg. to 100 mg. per Kg. body weight per day, which may be administered in a single dose or in divided doses.

The invention is further illustrated by the following non-limiting Examples. In the Examples, all of the values for specific rotation were measured using the sodium D line, i.e. all values are [α] D .

›Examples25

›EXAMPLE 1

Ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoate (Compound No. 5)

(a)

250 mg (0.5 mmole) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidine hydrazide were dissolved in 8 ml of dimethylformamide, and 0.42 ml of 4.0N hydrogen chloride/dioxane were added to the solution, and the mixture was cooled to -60° C.

0.1 ml of isoamyl nitrite was added to the resulting solution, and then the reaction temperature was elevated to -20° C. The disappearance of the hydrazide was confirmed, and then the temperature of the mixture was again lowered to -60° C. The mixture was then neutralized by the addition of 0.17 g of N-methylmorpholine, to give a solution of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidine azide.

(b)

Meanwhile, 5 ml of 6N hydrogen chloride/dioxane were added to 152 mg (0.5 mmole) of ethyl 4(S)-t-butoxycarbonylamino-3(S)-hydroxy-6-methylheptanoate. The solution was stirred for 20 minutes under a nitrogen stream, and then concentrated by evaporation under reduced pressure, to give a solid residue. The resulting residue was dissolved in 2 ml of dimethylformamide, and 0.05 g of N-methylmorpholine was added to give a solution of ethyl 4(S)-amino-3(S)-hydroxy-6-methylheptanoate.

(c)

To the cooled azide solution prepared as described in (a) above was added dropwise the ethyl ester solution prepared as described in (b) above. The mixture was stirred at 4° C. for 20 hours, and then the solvent was removed by distillation under reduced pressure. To the resulting residue was added a 5% w/v aqueous solution of sodium bicarbonate, and then the precipitated gum-like substance was extracted with ethyl acetate. The organic extract was washed with water and then with a saturated aqueous solution of sodium chloride. The solution was then dried over anhydrous sodium sulfate, and the solvent was removed by distillation under reduced pressure. A 1:5 by volume mixture of ethyl acetate and diethyl ether was added to the resulting residue to precipitate a solid, which was separated, finely pulverized and filtered to give 163 mg of the title compound as a white powder, melting at 138°-140° C., [α] 24 -70.6° (C=0.5, methanol).

Elemental analysis: Calculated for C 37 H 45 N 5 O 7 : C, 66.15%; H, 6.75%; N, 10.43%. Found: C, 66.50%; H, 6.46%; N, 10.25%.

›EXAMPLE 2

4(S)-[N-Benzyloxycarbonyl-3-(1-napthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoic acid (Compound No. 3)

112 mg (0.17 mmole) of ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoate (prepared as described in Example 1) were dissolved in 3 ml of methanol, and 0.2 ml (0.2 mmole) of a 1N aqueous solution of sodium hydroxide was added to the resulting solution. The mixture was then stirred at room temperature for 6 hours, after which it was neutralized by the addition of 1N aqueous hydrochloric acid. The solvent was then removed from the resulting solution by distillation under reduced pressure. To the solid residue were added 5 ml of water and 2 ml of ethyl acetate to form a precipitate, which was crushed and separated by filtration. The resulting residue was washed with water and with a small amount of ethyl acetate, and then dried to give 49 mg of the title compound as a white powder, melting at 191°-192° C., [α] 24 -59.2° (C=0.3, methanol).

Elemental analysis: Calculated for C 35 H 41 N 5 O 7 : C, 65.94%; H, 6.30%, N 10.68%. Found: C, 66.21%; H, 6.03%; N, 10.51%.

›EXAMPLE 3

Phenyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanaoate (Compound No. 21)

(a) Phenyl 4(S)-t-butoxycarbonylamino-3(S)-hydroxy-6-methylheptanoate

371 mg of 2-fluoro-N-methylpyridine p-toluenesulfonate were dissolved in 1 ml of methylene chloride, and then 1 ml of a methylene chloride solution containing 300 mg of 4(S)-t-butoxycarbonylamino-3(S)-hydroxy-6-methylheptanoic acid, 103 mg of phenol and 484 mg of tributylamine was added under a nitrogen stream. The resulting solution was stirred at room temperature for 24 hours. It was then treated essentially as described in Example 1(b), and then separated by silica gel thin layer chromatography to give 144 mg of a colorless solid. Colorless prismatic crystals melting at 99°-100° C. were obtained by recrystallization from hexane.

Mass spectrum (m/e): 351 (M + ). [α] 24 -26.6° (C=0.5, methanol).

(b)

208 mg of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidine were dissolved in 4 ml of dimethylformamide, and 0.31 ml of 4.0N hydrogen chloride/dioxane were added to the resulting solution which was then cooled to -60° C. 52 mg of isoamyl nitrite were then added to the resulting mixture, after which the reaction temperature was raised to -20° C. The disappearance of the hydrazide was confirmed, and then the temperature of the mixture was lowered to -60° C., and 126 mg of triethylamine were added to give an azide solution.

(c)

3 ml of 6N hydrogen chloride/dioxane were added under a nitrogen stream to 112 mg of phenyl 4(S)-t-butoxycarbonylamino-3(S)-hydroxy-6-methylheptanoate [prepared as desribed in (a) above]. The mixture was then stirred for 30 minutes, after which the solvent was removed by distillation under reduced pressure. The resulting residue was dissolved in 1 ml of dimethylformamide, and 64 mg of triethylamine were added to prepare a solution of phenyl 4(S)-amino-3(S)-hydroxy-6-methylheptanoate.

(d)

To the cool azide solution prepared as described in (b) above was added the phenyl ester solution prepared as described in (c) above. The mixture was stirred at 4° C. for 2 days and then the solvent was removed by distillation under reduced pressure. The resulting residue was treated in the same way as described in Example 1(c), and was then purified by silica gel column chromatography, eluted with a 20:1 by volume mixture of chloroform and methanol and triturated with diethyl ether, to afford 25 mg of the title compound as a colorless powder, melting at 103°-106° C., [α] 24 -28.7° C. (C=0.3 methanol).

›EXAMPLE 4

Benzyl 4(S)-[N-benzyloxycrbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoate (Compound No. 15)

(a) Benzyl 4(S)-t-butoxycarbonylamino-3(S)-hydroxy-6-methylheptanoate

275 mg of 4(S)-t-butoxycarbonylamino-3(S)-hydroxy-6-methylheptanoic acid and 181 mg of dicyclohexylamine were dissolved in 3 ml of dimethylformamide, and then 171 mg of benzyl bromide were added to the resulting solution, which was then stirred at room temperature for 24 hours. The resulting solution was then diluted with ethyl acetate, washed with a saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate. The solvent was removed by distillation under reduced pressure, and the resulting residue was purified by silica gel thin layer chromatography, using a 4:1 by volume mixture of benzene and ethyl acetate as the developing solvent, to afford 220 mg of a colorless oily substance.

Mass spectrum (m/e): 366.2283 (M+1). [α] 24 -27.1° (C=1, methanol).

(b) Benzyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoate

The procedure described in Example 1(c) was repeated, but using 300 mg (0.6 mmole) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidine hydrazide and 180 mg of benzyl 4(S)-t-butoxycarbonylamino-3(S)-hydroxy-6-methylheptanoate. The resulting syrup was purified by silica gel column chromatography eluted with mixtures of chloroform and methanol ranging from 20:1 to 5:1. The solvent was removed by distillation under reduced pressure from the active fractions, and diethyl ether was added to the residue, to solidify it. This solid was finely pulverized and separated by filtration, giving 97 mg of the title compound as a white powdery solid, melting at 102°-109° C., [α] 24 -31.0° (C=0.5 methanol).

Elemental analysis: Calculated for C 42 H 47 N 5 O 7 : C, 68.74%; H, 6.46%; N, 9.54%. Found: C, 68.50%; H, 6.72%; N, 9.26%.

›EXAMPLE 5

4(S)-[N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoic acid hydrazide (Compound No. 38)

134 mg (0.2 mmole) of ethyl 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoate (prepared as described in Example 1) were dissolved in 2 ml of dimethylformamide, and 100 mg (2 mmole) of hydrazine hydrate were added to the resulting solution, which was then stirred at room temperature for 2 days. The solvent was then removed by distillation under reduced pressure, and water was added to the resulting residue to form a precipitate, which was filtered off. The resulting precipitate was washed thoroughly with water and then dissolved in methanol. The solvent was removed by distillation under reduced pressure. A 1:1 by volume mixture of diethyl acetate and diethyl ether was added to the resulting solid residue, which was then finely pulverized and filtered. There were obtained 112 mg of the title compound as a white powdery solid, melting at 120°-127° C., [α] 24 -58.6°. (C=0.5, dimethylformamide).

Elemental analysis: Calculated for C 35 H 43 N 7 O 6 : C, 63.91%; H, 6.59%; N, 14.91%. Found: C, 63.70%; H, 6.65%; N, 14.76%.

›EXAMPLE 6

Methyl [1-{[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino}-3-methylbutylphosphinico]acetate (Compound No. 61)

(a) Methyl {1-(benzyloxycarbionylamino)-3-methylbutylphosphinico}acetate

100 ml of toluene were added to 2.1 g (0.0206 mole) of pivalic acid and 1.72 g (0.011 mole) of benzyl carbamate, and the mixture was stirred, whilst heating. A small amount of water was removed by distilling off about 20 ml of toluene. The remaining toluene solution was cooled to room temperature and 2 g of a powdery 0.4 nm molecular sieve was added under a nitrogen stream, and then 1.8 g (0.010 mole) of (carbomethoxymethyl)dichlorophosphine (prepared as described in EP publication No. 63,896) were added and the whole was stirred. To the resulting mixture was added 0.97 g (0.011 mole) of 3-methylbutyraldehyde dropwise over a period of 5 minutes. Generation of a little heat was observed. The mixture was stirred for 16 hours, and then filtered. The filtrate was concentrated by evaporation under reduced pressure. To the residual solution, were added 100 ml of water and the pH was adjusted to 8-9 by the addition of a saturated aqueous solution of sodium carbonate, and then the resulting solution was washed with diethyl ether. The pH value was adjusted to 1-2 with concentrated hydrochloric acid, and then the solution was extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium chloride and then dried over anhydrous magnesium sulfate. The ethyl acetate solution was concentrated by evaporation under reduced pressure, and the product was reprecipitated from a mixture of methylene chloride and hexane, and washed with a small amount of diethyl ether to afford 0.38 g of the title compound, melting at 133°-135° C.

Rf value=0.63 [thin layer chromatography, Silica gel; developing solvent: methanol/acetic acid/methylene chloride (1:1:8 by volume)].

Elemental analysis: Calculated for C 16 H 24 NO 6 P: C, 53.78%; H, 6.77%; N, 3.92%; P, 8.67%. Found: C, 53.76%; H, 6.85%; N, 3.83%, P, 8.46%.

Mass spectrum (m/e): 357.36(M + ).

(b)

Following the same procedure as described in Example 1, 100 mg (0.20 mmole) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl hydrazide were dissolved in 1 ml of dimethylformamide, and 0.2 ml of 4N hydrogen chloride/dioxane was added to make the solution acidic. 30 mg (0.26 mmole) of isoamyl nitrite were then added, whilst ice-cooling and stirring. The disappearance of the hydrazide was confirmed, and then triethylamine was added to make the resulting azide solution basic.

Meanwhile, the benzyloxycarbonyl group was removed from 70 mg (0.20 mmole) of the phosphinic acid compound synthesized as described in (a) above by catalytic hydrogenation using a 10% w/w palladium-on-carbon catalyst. The resulting compound was added to the azide solution, and the mixture was stirred at 4° C. for 4 days, keeping the solution basic. Water was added, and the mixture was extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium chloride, and then dried over anhydrous magnesium sulfate. The ethyl acetate solution was concentrated by distillation under reduced pressure, and the residue was isolated by reverse phase high performance chromatography (eluent: 90% v/v aqueous methanol). Reprecipitation from a mixture of methylene chloride and diethyl ether afforded 7 mg of the title compound as a white powder, melting at 141°-146° C., [α] 24 -3.0° (C=0.1, methanol).

Molecular formula and molecular weight C 35 H 42 N 5 O 8 P 1 =691.741. FAB/MS Cation 692 (M+H) + . FAB/MS Anion 690 (M-H) - . (FAB/MS is Fast Atom Bombardment Mass Spectrometry).

According to the above data, the molecular weight was determined to be 691.

›EXAMPLE 7

1-{4(S)-[N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-4-phenylpiperidine (Compound No. 36)

A mixture of 137 mg (0.5 mmole) of 4(S)-t-butoxycarbonylamino-3(S)-hydroxy-6-methylheptanoic acid, 117 mg (1 mmole) of 1-hydroxybenztriazole and 161 mg (1 mmole) of 4-phenylpiperidine was dissolved in 30 ml of methylene chloride.

To the resulting solution, were added 355 mg (2 mmole) of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, and the resulting mixture was stirred at room temperature for 20 hours. The solvent was then distilled from the mixture. Ethyl acetate was added to the resulting residue, and the ethyl acetate layer was separated and washed with, in turn, a 5% w/v aqueous solution of sodium bicarbonate, water, a 5% w/v aqueous solution of citric acid and water, and dried over anhydrous sodium sulfate. Ethyl acetate was distilled from the extract under reduced pressure, to give 1-[4(S)-t-butoxycarbonylamino-3(S)-hydroxy-6-methylheptanoyl]-4-phenylpiperidine as an oil.

This substance showed an Rf value of 0.85 (developing solvent:chloroform/methanol=9:1 by volume) on thin layer chromatography using a silica gel plate. Its t-butoxycarbonyl radical was removed by the same procedure as described in Example 1(b), and the resulting compound was reacted in dimethylformamide at 5° C. for 24 hours with the azide prepared from N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl hydrazide (0.5 mmole). The dimethylformamide was then distilled off, and a 5% w/v aqueous solution of sodium bicarbonate was added to the resulting residue. The product was then extracted with ethyl acetate. The ethyl acetate layer was washed with, in turn, water, a 5% w/v aqueous solution of citric acid and water, and then dried over anhydrous sodium sulfate, after which it was concentrated by evaporation under reduced pressure.

When petroleum ether was added to the resulting residue, the desired product was precipitated. Further reprecipitation as carried out using a mixture of ethyl acetate and petroleum ether. The combined precipitates were collected by filtration and dried to give 82 mg of the title product, melting at 184°-187° C., [α] 24 -56.0° (C=0.1, methanol).

Elemental analysis: Calculated for C 46 H 54 O 6 N 6 : C, 70.20%; H, 6.92%; N, 10.68%. Found: C, 69.85%; H, 6.71%; N, 10.45%.

›EXAMPLE 8

Methyl 3(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-2(S)-hydroxy-5-methylhexanoate (Compound No. 62)

(a) Methyl 3(S)-t-butoxycarbonylamino-2(S)-hydroxy-5-methylhexanoate

A solution of 1.00 g (3.8 mmole) of 3(S)-t-butoxycarbonylamino-2-hydroxy-5-methylhexanoic acid prepared by the method of R. L. Johnson [J. Med. Chem., 25, 605 (1982)] in 30 ml, of methanol was stirred, whilst cooling with ice, and then a diethyl ether solution of diazomethane was added and the mixture was stirred at room temperature for 1 hour. The solvent was then distilled off and the resulting solid was recrystallized from hexane to give 952 mg of the title product as colorless needles, melting at 84°-85° C.; [α] 25 -10.2° (C=1.26, methanol).

Elemental analysis: Calculated for C 13 H 25 NO 5 : C, 56.71%; H, 9.15%; N, 5.08%. Found: C, 56.57%; H, 9.09%; N, 4.97%.

Nuclear Magntic Resonance Spectrum (CDCl 3 ) δ ppm: 0.91 (6H, doublet, J=7.5 Hz, CH 3 ×2); 1.45 (9H, singlet, t-butyl); 3.17 (1H, doublet, J=6 Hz, OH); 3.80 (3H, singlet, OCH 3 ); 3.90-4.27 (1H, multiplet, NHCH); 4.35 (1H, doublet of doublets, J=3 & 6 Hz, CHCO 2 CH 3 ); 4.53-4.96 (1H, multiplet, NH).

Mass spectrum (m/e): 275 (M + ).

Infrared Absorption Spectrum (Nujol-trade mark-mull) ν max cm -1 : 3375 (OH), 1740 (CO of ester).

(b)

The procedure described in Example 1 was repeated, but using 95 mg (0.19 mmole) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidine hydrazide and 52 mg (0.19 mmole) of methyl 3(S)-t-butoxycarbonylamino-2(S)-hydroxy-5-methylhexanoate.

There were obtained 84 mg of the title product as a white powdery solid, melting at 110°-114° C.; [α] 24 -53.2° (C=0.5, methanol).

Elemental analysis: Calculated for C 35 H 41 N 5 O 7 : C, 65.20%; H, 6.42%; N, 10.88%. Found: C, 64.92%; H, 6.54%; N, 10.60%.

›EXAMPLE 9

1-{4(S)-[N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamido}-4-(3-trifluoromethylphenyl)piperazine (Compound No. 63)

The procedure described in Example 7 was repeated, but using 230 mg (1 mmole) of 4-(3-trifluoromethylphenyl)piperazine, to afford 1-[-4(S)-t-butoxycarbonylamino-3(S)-hydroxy-6-methylheptanamido]-4-(3-trifluoromethylphenyl)piperazine as a solid melting at 107°-109° C. Its t-butoxycarbonyl radical was removed by the same procedure as described in Example 1(b), and the procedure described in Example 7 was repeated but using the azide prepared from 250 mg (0.5 mmole) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl hydrazide to give 188 mg of the title compound as a white powdery solid, melting at 179°-181° C., [α] 24 -30.0° (C=0.5, methanol).

Elemental analysis: Calculated for C 46 H 52 N 7 O 6 F 3 : C, 65.62%; H, 6.23%; N, 11.40%. Found: C, 65.35%; H, 6.51%; N, 11.24%.

›EXAMPLE 10

4(S)-[N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-N-butyl-3(S)-hydroxy-6-methylheptanamide (Compound No. 64)

The procedure described in Example 7 was repeated but using 73 mg (1 mmole) of butylamine to afford 4(S)-t-butoxycarbonylamino-N-butyl-3(S)-hydroxy-6-methylheptanamide as an oily substance. This substance showed an Rf value of 0.72 (developing solvent: chloroform/methanol=9:1 by volume) on thin layer chromatography. Its t-butoxycarbonyl radical was removed by the same procedure as described in Example 1(b), and then the same procedure as described in Example 7 was repeated, but using the azide prepared from 250 mg of (0.5 mmole) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl hydrazide, to give 75 mg of the title compound as a white powdery solid melting at 169°-171° C., [α] 22 -18.0° (C=0.5, methanol).

Elemental analysis: Calculated for C 39 H 50 N 6 O 6 : C, 67.02%; H, 7.21%; N, 12.03%. Found: C, 66.87%; H, 7.50%; N, 11.89%.

›EXAMPLE 11

4(S)-[N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methyl-N-[S-(-)-2-methylbutyl]heptanamide (Compound No. 65)

The procedure described in Example 7 was repeated, but using 87 mg (1 mmole) of (S)-(-)-2-methylbutylamine to afford 4(S)-t-butoxycarbonyl-3(S)-hydroxy-6-methyl-N-[(S)-(-)-2-methylbutyl]heptanamide as a solid melting at 83°-84° C. Its t-butoxycarbonyl group was removed by the same procedure as described in Example 1(b), and then the procedure described in Example 7 was repeated, but using the azide prepared from 250 mg (0.5 mmole) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl hydrazide to give 180 mg of the title compound as a white powdery solid melting at 164°-166° C., [α] 22 -6.8° (C=0.5, methanol).

Elemental analysis: Calculated for C 40 H 52 N 6 O 6 : C, 67.39%; H, 7.35%; N, 11.79%. Found: C, 67.10%; H, 7.61%; N, 11.52%.

›EXAMPLE 12

4(S)-[N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-N-ethyl-3(S)-hydroxy-6-methylheptanamide (Compound No. 66)

(a) 4(S)-t-Butoxycarbonylamino-N-ethyl-3(S)-hydroxy-6-methylheptanamide

275 mg (1 mmole) of 4(S)-t-butoxycarbonylamino-3(S)-hydroxy-6-methylheptanoic acid and 197 mg (1.1 mmole) of N-hydroxy-5-norbornene-2,3-dicarboximide were dissolved in 10 ml of methylene chloride and ice-cooled. To this solution were added 227 mg (1.1 mmole) of dicyclohexylcarbodiimide, and the mixture was stirred for 1 hour whilst ice-cooling and for a further 2 hours at room temperature. 90 mg (1.1 mmole) of ethylamine hydrochloride and 111 mg (1.1 mmole) of N-methylmorpholine were then added and the reaction mixture was stirred overnight at room temperature. The precipitated dicyclohexylurea was removed by filtration, and the filtrate was concentrated by evaporation under reduced pressure. A 10% w/v aqueous solution of citric acid was added to the resulting residue, and the precipitated oily substance was extracted with ethyl acetate. The organic extract was washed with, in turn, a 10% w/v aqueous solution of citric acid, water, a 5% w/v aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate and concentrated by evaporation under reduced pressure. Diethyl ether was added to the oily residue to remove insoluble matter, and the filtrate was concentrated by evaporation under reduced pressure. Hexane was added to the resulting oily residue, to solidify it, and the solid was reprecipitated from a 2:1 by volume mixture of hexane and diethyl ether and filtered to give the title compound as a white powdery solid melting at 103°-107° C., [α] 23 -43.6° (C=0.5, methanol).

Elemental analysis: Calculated for C 15 H 30 N 2 O 4 : C, 59.57%; H, 10.00%; N, 9.26%. Found: C, 59.40%; H, 9.89%; N, 9.41%.

(b) Compound No. 66

The t-butyloxycarbonyl group was removed from the compound produced as described in (a) above by the same procedure as described in Example 1(b), and then the procedure described in Example 7 was repeated but using the azide prepared from 250 mg (0.5 mmole) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl hydrazide to give 290 mg of the title compound as a white powdery solid melting at 184°-186° C., [α] 27 -60.2° (C=0.5, methanol).

Elemental analysis: Calculated for C 37 H 46 N 6 O 6 : C, 66.25%; H, 6.91%; N, 12.53%. Found: C, 65.85%; H, 6.63%; N, 12.40%.

›EXAMPLE 13

N 1 -{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-N 2 -(4-benzoylbutyryl)hydrazine (Compound No. 40)

66 mg (0.1 mmole) of 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoic acid hydrazide (prepared as described in Example 5) were dissolved in 3 ml of dimethylformamide, and then 31 mg (0.1 mmole) of N-hydroxysuccinimide 4-benzoylbutyrate were added and the mixture was stirred for 2 days at room temperature. The resulting reaction mixture was concentrated by evaporation under reduced pressure, and water was added to the resulting residue. After the water had been added to the residue, the precipitate was separated by filtration. It was washed with water, and the powder obtained after drying was washed with ethyl acetate, to give 63 mg of the title compound as a white powdery solid melting at 158°-160°, [α] 27 -44.4° (C=0.5, methanol).

Elemental analysis: Calculated for C 46 H 53 N 7 O 8 : C, 66.41%; H, 6.42%; N, 11.78%. Found: C, 66.18%; H, 6.59%; N, 11.65%.

›EXAMPLE 14

N-{4(S)-[N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol (Compound No. 67)

(a) N-[4(S)-t-Butoxycarbonylamino-3(S)-hydroxy-6-methylheptanoyl]-L-isoleucino

The procedure described in Example 12(a) was repeated but using 129 mg (1.1 mmole) of L-isoleucinol to afford 330 mg of the title compound as a white powdery solid melting at 91°-96° C., [α] 23 -46.6° (C=0.5, methanol).

Elemental analysis: Calculated for C 19 H 38 N 2 O 5 : C, 60.93%; H, 10.23%; N, 7.48%. Found: C, 60.95%; H, 10.18%; N, 7.53%.

(b) Compound No. 67

The procedure described in Example 7 was repeated but using 0.19 g (0.5 mmole) of the compound prepared as described in (a) above to give 112 mg of the title compound as a white powdery solid melting at 168°-171° C., [α] 23 -48.8° (C=0.5 methanol).

Elemental analysis: Calculated for C 41 H 54 N 6 O 7 : C, 66.28%; H, 7.33%; N, 11.31%. Found: C, 65.99%; H, 7.61%; N, 11.14%.

›EXAMPLE 15

4(S)-[N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-D-histidyl]amino-3(S)-hydroxy-6-methyl-N-[S-(-)-2-methylbutyl]heptanamide (Compound No. 93)

(a) 4(S)-(N-Benzyloxycarbonyl-D-histidyl)amino-3(S)-hydroxy-6-methyl-N-[S-(-)-2-methylbutyl]heptanamide

2.00 g (22.9 mole) of S-(-)-2-methylbutylamine and 6.00 g (21.8 mmole) of 4(S)-t-butoxycarbonylamino-3(S)-hydroxy-6-methylheptanoic acid were dissolved in 50 ml of anhydrous tetrahydrofuran, and 4.3 g of diethyl phosphorocyanidate (26.4 mmole) and 3.7 ml (26.5 mmole) of triethylamine were added dropwise to the solution under a nitrogen atmosphere. The mixture was stirred for 2 hours at room temperature. The reaction product was then condensed by evaporation under reduced pressure, and ethyl acetate was added to the residue. The mixture was washed with 10% w/v aqueous hydrochloric acid, a saturated solution of sodium bicarbonate, and a saturated solution of sodium chloride, in that order, and then dried over anhydrous magnesium sulfate. The dried mixture was condensed by evaporation under reduced pressure, and the residue was purified by silica gel column chromatography eluted with a 10:1 by volume mixture of chloroform and methanol to yield 5.1 g (68%) of the title compound.

The t-butoxycarbonyl group was removed from this compound using a mixture of 6N hydrochloric acid and dioxane as described in Example 1(b), to give 4(S)-amino-3(S)-hydroxy-6-methyl-N-[S-(-)-2-methylbutyl]heptanamide hydrochloride.

Meanwhile, 1.00 g (3.30 mmole) of N-benzyloxycarbonyl-D-histidine hydrazide was suspended in 20 ml of dimethylformamide, and 2.8 ml of a mixture of 4N hydrochloric acid and dioxane was added to the suspension, whilst cooling at -60° C. After completion of this addition, the reaction temperature was raised to -20° C., and 0.53 ml (3.95 mmole) of isoamyl nitrite was added to the mixture; the mixture was then stirred for 10 minutes. Disappearance of the hydrazide was confirmed, and then the mixture was cooled down to -60° C., after which 1.37 ml (12.5 mmole) of N-methylmorpholine was added for neutralization. 1.00 g (3.56 mmole) of 4(S)-amino-3(S)-hydroxy-6-methyl-N-[S-(-)-2-methylbutyl]heptanamide hydrochloride [prepared as described in (a) above] and 0.4 ml (3.64 mmole) of N-methylmorpholine were then added to the mixture, which was further stirred overnight at 4° C. The solvent was then distilled off under reduced pressure, and the residue was purified by silica gel column chromatography eluted with a 20:1 by volume mixture of chloroform and methanol, to yield 850 mg (48%) of white crystals of the monohydrate of the title compound melting at 77°-79° C., [α] 25 =-26.4 (C=0.5, methanol).

Elemental analysis: Calculated for C 27 H 43 N 5 O 6 : C, 60.77%; H, 8.12%; N, 13.12%. Found: C, 60.75%; H, 8.12%; N, 13.40%.

(b) Compound No. 93

700 mg (1.31 mmole) of the monohydrate of 4(S)-[N-benzyloxycarbonyl-D-histidyl]amino-3(S)-hydroxy-6-methyl-N-[S-(-)-2-methylbutyl]heptanamide were dissolved in 20 ml of ethanol, and 2.62 ml of 1N hydrochloric acid and 70 mg of 10% w/v palladium-on-carbon were added to the solution, which was then stirred for 4 hours at room temperature in a hydrogen atmosphere to remove the benzyloxycarbonyl group. The solvent was then distilled off under reduced pressure. 20 ml of anhydrous tetrahydrofuran were added to the residue, and 400 mg (1.14 mmole) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanine were also dissolved in the mixture. 0.2 ml (1.32 mmole) of diethyl phosphorocyanidate and 0.6 ml (4.30 mmole) of triethylamine were then added dropwise, with ice cooling, under a nitrogen atmosphere, and the mixture was stirred for 6 hours at room temperature. The reaction product was condensed by evaporation under reduced pressure, and ethyl acetate was added to the residue. The mixture was washed with water and dried over anhydrous magnesium sulfate. The dried product was condensed by evaporation under reduced pressure, and the residue was purified by silica gel preparative thin layer chromatography, using a 5:1 by volume mixture of chloroform and methanol as developing solvent, to yield 450 mg (54%) of white crystals of the monohydrate of the title compound melting at 108°-110° C., [α] 25 =-22.0° (C=0.5, methanol).

Elemental analysis: Calculated for C 40 H 54 N 6 O 7 : C, 65.73%; H, 7.45%; N, 11.49%. Found: C, 65.56%; H, 7.32%; N, 11.20%.

›EXAMPLE 16

4(S)-[N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methyl-N-[S-(-)-2-methylbutyl]heptanamide (Compound No. 207)

(a) 4(S)-[N-benzyloxycarbonyl-L-leucyl]amino-3(S)-hydroxy-6-methyl-N-[S-(-)-2-methylbutyl]heptanamide

280 mg (1 mmole) of 4(S)-amino-3(S)-hydroxy-6-methyl-N-[S-(-)-2-methylbutyl]heptanamide hydrochloride were dissolved in 5 ml of methylene chloride, and 111 mg (1.1 mmole) of N-methylmorpholine were added to the solution, whilst ice cooling, to neutralize it. 398 mg (1.1 mmole) of N-benzyloxycarbonyl-L-leucine N-hydroxysuccinimide ester were then added, and the mixture was stirred overnight at room temperature. 0.5 ml of N,N'-dimethylaminopropylamine was then added, and the mixture was stirred for 1 hour at room temperature to allow the amine to react with any excess of active ester. The reaction product was then condensed by evaporation under reduced pressure, and 1N hydrochloric acid was added to the residue. The oily substance isolated by this addition was extracted with ethyl acetate. The organic extract was washed with water, with a 5% w/v aqueous solution of sodium bicarbonate, and with a saturated aqueous solution of sodium chloride, and was then condensed by evaporation under reduced pressure. The resulting solid residue was then purified by silica gel column chromatography eluted with mixtures of benzene and ethyl acetate ranging from 4:1 to 2:1 by volume. The fraction containing the desired compound was collected and condensed by evaporation under reduced pressure. Diethyl ether was added with thorough grinding to the condensate, and then the precipitate was collected by filtration to yield 297 mg of the title compound as a colorless powder melting at 146°-149° C.

Elemental analysis: Calculated for C 27 H 45 N 3 O 5 : C, 65.95%; H, 9.23%; N, 8.55%. Found: C, 65.88%; H, 9.30%; N, 8.66%.

(b) Compound No. 207

The benzyloxycarbonyl group was removed from 246 mg (0.5 mmole) of the compound prepared as described in (a) above by catalytic hydrogenation using 5% w/v palladium-on-carbon as a catalyst according to the method described in Example 15(b), giving L-leucyl-4(S)-amino-3(S)-hydroxy-6-methyl-N-[S-(-)-2-methylbutyl]heptanamide hydrochloride. This was then dissolved in 2 ml of dimethylformamide, neutralized with 55 mg (0.5 mmole) of N-methylmorpholine, and stirred at 0° C. for 2.5 hours.

Meanwhile, 175 mg (0.5 mmole) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanine and 61 mg (0.6 mmole) of N-methylmorpholine were dissolved in 10 ml of anhydrous tetrahydrofuran, and the solution was cooled down to -5° C. Whilst cooling, 65 mg (0.6 mmole) of ethyl chlorocarbonate was added dropwise to the solution, which was then stirred for 15 minutes.

The above-mentioned solution of L-leucyl-4(S)-amino-3(S)-hydroxy-6-methyl-N-[S-(-)-2-methylbutyl]heptanamide hydrochloride was then added and the mixture was left standing overnight at room temperature. The product was then condensed by evaporation under reduced pressure. Water was added to the residue, and the resulting precipitate was collected by filtration. The precipitate was thoroughly washed on the glass filter with a 1:1 by volume mixture of diethyl ether and ethyl acetate and then collected thereon by filtration, to yield 265 mg of the title compound as a colorless powder melting at 226°-229° C., [α] 23 -69.7° (C=0.3, dimethylformamide.

Elemental analysis: Calculated for C 40 H 56 N 4 O 6 .1/2H 2 O: C, 68.84%; H, 8.23%; N, 8.03%. Found: C, 68.83%; H, 8.19%; N, 8.22%.

›EXAMPLE 17

N-{4(S)-[N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol (Compound No. 208)

(a) N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucine hydrazide

3.49 g (10 mmole) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanine and 1.21 g (12 mmole) of N-methylmorpholine were dissolved in 30 ml of anhydrous tetrahydrofuran, and then, whilst cooling the solution at -5° C., 1.30 g (12 mmole) of ethyl chlorocarbonate was added dropwise, with stirring, over a period of 15 minutes. 2.35 g (12 mmole) of L-leucine ethyl ester hydrochloride [which had been suspended in 10 ml of methylene chloride and neutralized with 1.21 g (12 mmole) of N-methylmorpholine] were added. The mixture was stirred for 2 hours with ice cooling, and then left standing overnight at room temperature. It was then condensed by evaporation under reduced pressure. Water was added to the residue, and the precipitating oily substance was extracted with ethyl acetate. The organic extract was washed with 1N hydrochloric acid, water, a 5% w/v aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride, in that order, and then dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure. The N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucine ethyl ester thus obtained in a syrupy form was dissolved in 30 ml of dimethylformamide, and 5.06 g (100 mmole) of hydrazine hydrate were added to the solution. The mixture was stirred for 36 hours at room temperature. The reaction product was then condensed by evaporation under reduced pressure, and water was added to the residue. The colorless crystals produced were collected by filtration, thoroughly washed with water and dried in a desiccator to yield 4.23 g of the title compound melting at 200°-204° C.

Elemental analysis: Calculated for C 27 H 32 N 4 O 4 : C, 68.04%; H, 6.77%; N, 11.76%. Found: C, 68.32%; H, 6.73%; N, 11.90%.

(b) N-{4(S)-[N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

477 mg (1 mmole) of the hydrazide produced as described in step (a) above were dissolved in 8 ml of dimethylformamide, and the solution was cooled to -60° C. 0.84 ml of 4.0N hydrogen chloride in dioxane and 0.18 ml of isoamyl nitrite were added. The reaction temperature was then raised to -20° C. with stirring for 10 minutes. Disappearance of the hydrazide was confirmed, and then the temperature of the product was lowered again to -60° C. 0.45 g of N-methylmorpholine was added to neutralize the solution and yield a solution of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucine hydrazide.

Meanwhile, the t-butoxycarbonyl group was removed from 412 mg (1.1 mmole) of 4(S)-t-butoxycarbonylamino-3(S)-hydroxy-6-methylheptanoyl-L-isoleucinol with 6N hydrogen chloride in dioxane, as described in Example 1(b), to yield 4(S)-amino-3(S)-hydroxy-6-methylheptanoyl-L-isoleucinol hydrochloride. This product was dissolved in 5 ml of dimethylformamide, and the resulting solution was added to the above-mentioned hydrazide solution, and the mixture was stirred at 4° C. for 7 days. The solvent was distilled off under reduced pressure. Water was added to the residue, and the oily substance produced was extracted with ethyl acetate. The organic extract was washed with 1N hydrochloric acid, water, a 5% w/v aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride, in that order, and dried over anhydrous sodium sulfate. It was then condensed by evaporation under reduced pressure. The syrupy residue was purified by silica gel preparative thin layer chromatography, using a 5:1 by volume mixture of chloroform and methanol as the developing solvent. The active fractions extracted with ethyl acetate. The extract was washed with water and with a saturated aqueous solution of sodium chloride, dried, and then condensed by evaporation under reduced pressure. On adding diethyl ether to the residues, the condensate solidified, and this was finely ground and then collected by filtration to yield 402 mg of the title compound as a colorless powder melting at 206°-212° C., [α] 23 -95.0° (C=0.3, methanol).

Elemental analysis: Calculated for C 41 H 58 N 4 O 7 : C, 68.49%; H, 8.13%; N, 7.29%. Found: C, 68.46%; H, 7.94%; N, 7.87%.

›EXAMPLE 18

N-{4(S)-[N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-thienyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol (Compound No. 218)

(a) 3-(2-Thienyl)-DL-alanine methyl ester hydrochloride

3.78 g (0.0318 mole) of thionyl chloride were added dropwise at -5° C. to 10.2 g (0.318 mole) of methanol. After 5 minutes, 3.3 g (0.0159 mole) of 3-(2-thienyl)-DL-alanine hydrochloride were added gradually to this solution, whilst keeping the temperature at -5° C. The mixture was then stirred for 3 hours at this temperature, and then left standing for 24 hours at room temperature. The reaction product was then condensed by evaporation under reduced pressure, and ethanol was added to the residue. The mixture was then condensed by evaporation under reduced pressure and 3.53 g (yield 100%) of 3-(2-thienyl)-DL-alanine methyl ester hydrochloride melting at 110°-112° C. were obtained as the residue.

(b) N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-thienyl)-DL-alanine methyl ester

A mixed solution of 1.11 g (5 mmole) of 3-(2-thienyl)-DL-alanine methyl ester hydrochloride and 1.75 g (5 mmole) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanine in 15 ml of dimethylformamide was cooled with ice water, and then 1.11 g (11 mmole) of triethylamine was added with stirring. After that, 0.83 g (5 mmole) of diethyl phosphorocyanidate was added, and the mixture was stirred for 3 hours at room temperature. Subsequently, the reaction product was poured into ice water, and the mixture was extracted with ethyl acetate. The extract was washed with water, then dried, and finally purified by thin layer chromatography, yielding 1.9 g (73.6%) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-thienyl)-DL-alanine methyl ester melting at 140°-141° C.

A mixed solution of 1.0 g (194 mmole) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-thienyl)-DL-alanine methyl ester and 0.64 g (0.2 mmole) of 80% hydrazine hydrate in 10 ml of dimethylformamide was stirred for 2 hours at room temperature and then left standing overnight at room temperature. Dimethylformamide was removed by evaporation under reduced pressure. Water was added to the residue, and the mixture was stirred to form a powdery precipitate, which was collected by filtration, washed with a mixture of diethyl ether and hexane and dried to yield 1.0 g (100%) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-thienyl)-DL-alanine hydrazide melting at 163°-164° C.

(d) Compound No. 218

517 mg (1 mmole) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-thienyl)-DL-alanine hydrazide were dissolved in 10 ml of dimethylformamide, and the solution was cooled down to -60° C. 0.85 ml (3.4 mmole) of 4N hydrogen chloride in dioxane was then added. The temperature of this mixture was elevated to -20° C., and then 0.16 ml (1.19 mmole) of isoamyl nitrile was added and the mixture was stirred for 10 minutes. The reaction product was again cooled down to -60° C., and 0.42 ml (3.82 mmole) of N-methylmorpholine was added for neutralization. Subsequently, 370 mg (1.2 mmole) of 4(S)-amino-3(S)-hydroxy-6-methylheptanoyl-L-isoleucinol hydrochloride were added, and the mixture was stirred for 30 minutes. The reaction product was stirred overnight at 0° C., condensed by evaporation under reduced pressure and purified by thin layer chromatography, using as developing solvent a 99:1 by volume mixture of chloroform and methanol, to yield 100 mg (13.2%) of the title compound melting at 160°-162° C., [α] 23 -61.7° (C=0.3, dimethylformamide).

Elemental analysis: Calculated for C 42 H 54 N 4 O 7 S: C, 66.47%; H, 7.17%; N, 7.38%; S, 4.22%. Found: C, 66.22%; H, 6.99%; N, 7.39%; S, 4.42%.

›EXAMPLE 19

N-{4(S)-[N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-thiazolyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol (Compound No. 228)

(a) N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-thiazolyl)-DL-alanine hydrazide

2.90 g (8.30 mmole) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanine and 2.15 g (8.30 mmole) of 3-(4-thiazolyl)-DL-alanine methyl ester dihydrochloride were suspended in 30 ml of anhydrous tetrahydrofuran. Whilst ice cooling, 1.51 ml (9.95 mmole) of diethyl phosphorocyanidate and 3.82 ml (27.4 mmole) of triethylamine were added dropwise under a nitrogen gas stream, and the mixture was stirred overnight at room temperature. The reaction product was condensed by evaporation under reduced pressure. Ethyl acetate was added to the residue, and the mixture was washed with water and then dried over anhydrous magnesium sulfate. The dried product was condensed by evaporation under reduced pressure, and the residue was purified by silica gel column chromatography eluted with a 10:1 by volume mixture of chloroform and methanol, to yield 2.62 g (61%) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-thiazolyl)-DL-alanine methyl ester.

2.10 g (4.06 mmole) of this ester were dissolved in 20 ml of dimethylformamide, and then 2.00 g (40.0 mmole) of hydrazine hydrate were added; the mixture was stirred overnight at room temperature. This reaction product was condensed by evaporation under reduced pressure, and then water was added to the residue. The precipitating crystals were collected by filtration, washed with hexane and diethyl ether and dried, to yield 1.90 g (90.5%) of the title compound.

(b) N-{4(S)-[N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-thiazolyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol

400 mg (0.77 mmole) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-thiazolyl)-DL-alanine hydrazide were suspended in 10 ml of dimethylformamide, and this suspension was cooled down to -60° C., at which temperature 0.66 ml of 4N hydrogen chloride in dioxane was added. The reaction temperature was raised to -20° C., and then 0.13 ml (0.97 mmole) of isoamyl nitrite was added, and the mixture was stirred for 10 minutes. Disappearance of the hydrazide was confirmed, and then the mixture was again cooled down to -60° C., and 0.33 ml (3.00 mmole) of N-methylmorpholine was added for neutralization, followed by 328 mg (1.02 mmole) of 4(S)-amino-3(S)-hydroxy-6-methylheptanoyl-L-isoleucinol hydrochloride and 0.12 ml (1.09 mmole) of N-methylmorpholine. The solvent was distilled off under reduced pressure and the residue was purified by silica gel preparative thin layer chromatography using a 5:1 by volume mixture of chloroform and methanol as developing solvent, to yield 310 mg (52%) of the monohydrate of the title compound as white crystals melting at 167°-169° C., [α] 23 -31.3° (C=0.3, methanol).

Elemental analysis: Calculated for C 41 H 53 N 5 O 7 S.H 2 O: C, 63.29%; H, 7.13%; N, 9.00%; S, 4.12%. Found: C, 63.38%; H, 6.84%; N, 9.14%; S, 4.12%.

›EXAMPLE 20

4(S)-{N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-thiazolyl)-DL-alanyl}amino-3(S)-hydroxy-6-methyl-N-[2(RS)-phenylpropyl]heptanamide (Compound No. 243)

400 mg (0.77 mmole) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-thiazolyl)-DL-alanine hydrazide (synthesized as described in Example 16) were suspended in 10 ml of dimethylformamide, and the suspension was cooled down to -60° C. 0.66 ml of 4N hydrogen chloride in dioxane was added, and the reaction temperature was raised to -20° C. 0.13 ml (0.97 mmole) of isoamyl nitrite was added, and the mixture was stirred for 10 minutes. Disappearance of the hydrazide was confirmed, and then the reaction mixture was again cooled down to -60° C., and then 0.33 ml (3.00 mmole) of N-methylmorpholine was added for neutralization.

Meanwhile, 4(S)-t-butoxycarbonylamino-3(S)-hydroxy-6-methylheptanoic acid and 1-amino-2(RS)-phenylpropane were converted into the corresponding amides with diethyl phosphorocyanidate and triethylamine. Further, the t-butoxycarbonyl group was removed with 6N hydrogen chloride in a dioxane as described in Example 1(b), to synthesize 4(S)-amino-3(S)-hydroxy-6-methyl-N-[2(RS)-phenylpropyl]heptanamide hydrochloride.

335 mg (1.02 mmole) of this compound and 0.12 ml (1.09 mmole) of N-methylmorpholine were added to the above-mentioned reaction mixture, and the mixture was stirred at 4° C. overnight. The solvent was distilled off, and the residue was purified by silica gel preparative thin layer chromatography using a 5:1 by volume mixture of chloroform and methanol as the developing solvent, to yield 325 mg (53%) of the monohydrate of the title compound in the form of white crystals melting at 144°-146° C., [α] 23 -35.0° (C=0.3, methanol).

Elemental analysis: Calculated for C 44 H 51 N 5 O 6 S.H 2 O: C, 66.39%; H, 6.71%; N, 8.80%; S, 4.03%. Found: C, 66.86%; H, 6.49%; N, 9.06; S, 4.10%.

›EXAMPLE 21

4(S)-[N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-thiazolyl)-DL-alanyl]amino-3(S)-hydroxy-6-methyl-N-[2-(2-pyridyl)ethyl]heptanamide (Compound No. 241)

400 mg (0.77 mmole) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-thiazolyl)-DL-alanine hydrazide (synthesized as described in Example 16) were suspended in 10 ml of dimethylformamide, and the suspension was cooled down to -60° C. 0.66 ml of 4N hydrogen chloride in dioxane was added to the suspension, and the reaction temperature was raised to -20° C. At this temperature, 0.13 ml (0.97 mmole) of isoamyl nitrite was added, and the mixture was stirred for 10 minutes. Disappearance of the hydrazide was confirmed, and then the mixture was again cooled down to -60° C., at which temperature 0.33 ml (3.00 mmole) of N-methylmorpholine was added for neutralization.

Meanwhile, 4(S)-t-butoxycarbonylamino-3(S)-hydroxy-6-methylheptanoic acid and 2-(2-pyridyl)ethylamine were converted into an amide with diethyl phosphorocyanidate and triethylamine, and the t-butoxycarbonyl group was removed with 6N hydrogen chloride in dioxane as described in Example 1(b), to give 4(S)-amino-3(S)-hydroxy-6-methyl-N-[2-(2-pyridyl)ethyl]heptanamide dihydrochloride.

359 mg (1.02 mmole) of this compound and 0.22 ml (2.00 mmole) of N-methylmorpholine were added to the above-mentioned reaction mixture, and the mixture was stirred overnight at 4° C. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel preparative thin layer chromatography, using a 5:1 by volume mixture of chloroform and methanol as the developing solvent, to yield 301 mg (49%) of the 1.5 hydrate of the title compound in the form of pale brown crystals melting at 134°-136° C., [α] 23 -34.7° (C=0.3, methanol).

Elemental analysis Calculated for C 42 H 48 N 6 O 6 S.1.5H 2 O: C, 63.69%; H, 6.49%; N, 10.61%; S, 4.05%. Found: C, 63.50%; H, 6.14%; N, 10.48%; S, 4.16%.

›EXAMPLE 22

4(S)-[N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-thiazolyl)-DL-alanyl]amino-3(S)-hydroxy-6-methyl-N-(2-morpholinoethyl)heptanamide (Compound No. 242)

400 mg (0.77 mmole) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-thiazolyl)-DL-alanine hydrazide (synthesized as described in Example 16) was suspended in 10 ml of dimethylformamide, and the suspension was cooled down to -60° C., at which temperature 0.66 ml of 4N hydrogen chloride in dioxane was added to the suspension. The reaction temperature was then raised to -20° C., at which temperature 0.13 ml (0.97 mmole) of isoamyl nitrite was added to the suspension which was then stirred for 10 minutes. Disappearance of the hydrazide was confirmed, and then the suspension was again cooled down to -60° C., at which temperature 0.33 ml (3.00 mmole) of N-methylmorpholine was added to the suspension for neutralization.

Meanwhile, 4(S)-t-butoxycarbonylamino-3(S)-hydroxy-6-methylheptanoic acid and (2-morpholinoethyl)amine were converted into an amide with diethyl phosphorocyanidate and triethylamine. The t-butoxycarbonyl group was then removed with 6N hydrogen chloride in dioxane, as described in Example 1(b), to give 4(S)-amino-3(S)-hydroxy-6-methyl-N-(2-morpholinoethyl)heptanamide dihydrochloride.

350 mg (0.97 mmole) of this compound and 0.22 ml (2.00 mmole) of N-methylmorpholine were added to the above-mentioned reaction mixture, and the mixture was stirred overnight at 4° C. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel preparative thin layer chromatography, using a 5:1 by volume mixture of chloroform and methanol as the developing solvent, to yield 290 mg (47%) of the 1.5 hydrate of the title compound in the form of white crystals, melting at 132°-136° C., [α] 23 -34.3° (C=0.3, methanol).

Elemental analysis: Calculated for C 41 H 52 N 6 S.1.5H 2 O: C, 61.55%; H, 6.93%; N, 10.50%; S, 4.00%. Found: C, 61.10%; H, 6.30%; N, 10.47%; S, 4.14%.

›EXAMPLE 23

N-}(S)-[N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol (Compound No. 259)

(a) N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyridyl)-DL-alanine hydrazide

3.00 g (8.59 mmole) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanine and 1.40 g (7.77 mmole) of 3-(2-pyridyl)-DL-alanine methyl ester were dissolved in 30 ml of anhydrous tetrahydrofuran, and then 1.3 ml (8.57 mmole) of diethyl phosphorocyanidate and 1.2 ml (8.60 mmole) of triethylamine were added dropwise under a nitrogen gas stream. The mixture was stirred overnight at room temperature.

The mixture was then condensed by evaporation under reduced pressure. Ethyl acetate was added to the residue, and the mixture was washed with water, dried over anhydrous magnesium sulfate and condensed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography eluted with a 10:1 by volume mixture of chloroform and methanol, to yield 3.05 g (76.8%) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyridyl)-DL-alanine methyl ester.

3.00 g (5.86 mmole) of this compound were dissolved in 20 ml of dimethylformamide, and then 2.80 g (55.9 mmole) of hydrazine monohydrate were added to the solution, and the mixture was stirred overnight at room temperature. The reaction product was condensed by evaporation under reduced pressure, and water was added to the residue. The crystals produced were collected by filtration, washed with hexane and diethyl ether and dried to yield 2.93 g (97.7%) of the title compound.

(b) Compound No. 259

512 mg (1.00 mmole) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyridyl)-DL-alanine hydrazide were suspended in 10 ml of dimethylformamide, and the suspension was cooled down to -60° C., at which temperature 0.85 ml of 4N hydrogen chloride in dioxane was added. The reaction temperature of this mixture was then raised to -20° C., at which temperature 0.16 ml (1.19 mmole) of isoamyl nitrite was added, and the mixture was stirred for 10 minutes. Disappearance of the hydrazide was confirmed, and then the suspension was again cooled down to -60° C., at which temperature 0.42 ml (3.82 mmole) of N-methylmorpholine was added for neutralization. 386 mg (1.20 mmole) of 4(S)-amino-3(S)-hydroxy-6-methylheptanoyl-L-isoleucinol hydrochloride and 0.13 ml (1.18 mmole) of N-methylmorpholine were added to the mixture, which was stirred overnight at 4° C.

The solvent was then distilled off under reduced pressure, and the residue was purified by silica gel preparative thin layer chromatography, using a 5:1 by volume mixture of chloroform and methanol as the developing solvent, to yield 300 mg (38%) of the 1.5 hydrate of the title compound in the form of pale brown crystals melting at 153°-155° C., [α] 23 -49.7° (C=0.3, methanol).

Elemental analysis: Calculated for C 43 H 55 N 5 O 7 .1.5H 2 O: C, 66.13%; H, 7.49%; N, 8.97%. Found: C, 66.14%, H, 7.22%; N, 8.93%.

›EXAMPLE 24

4(S)-[N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methyl-N-[2(RS)-phenylpropyl]heptanamide (Compound No. 263)

512 mg (1.00 mmole) of N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyridyl)-DL-alanine hydrazide (synthesized as described in Example 23) were suspended in 10 ml of dimethylformamide, and the suspension was cooled down to -60° C., at which temperature 0.85 ml of 4N hydrogen chloride in dioxane was added. The reaction temperature was then raised to -20° C., at which temperature 0.16 ml (1.19 mmole) of isoamyl nitrite was added to the mixture and stirred for 10 minutes. Disappearance of the hydrazide was confirmed, and then the mixture was again cooled down to -60° C., and 0.42 ml (3.82 mmole) of N-methylmorpholine was added to the reaction mixture for neutralization.

395 mg (1.20 mmole) of 4(S)-amino-3(S)-hydroxy-6-methyl-N-[2(RS)-phenylpropyl]heptanamide hydrochloride and 0.18 ml (1.64 mmole) of N-methylmorpholine were then added to the reaction mixture, which was then stirred overnight at 4° C. The solvent was distilled off, and the residue was purified by silica gel preparative thin layer chromatography, using a 5:1 by volume mixture of chloroform and methanol, to yield 326 mg (41%) of the 1.5 hydrate of the title compound in the form of pale brown crystals melting at 141°-145° C., [α] 23 -36.7° (C=0.3, methanol).

Elemental analysis: Calculated for C 46 H 53 N 5 O 6 .1.5H 2 O: C, 69.15%; H, 7.06%; N, 8.77%. Found: C, 69.10%; H, 6.65%; N, 9.04%.

›EXAMPLE 25

4(S)-[N-Benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyridyl)-DL-alanyl]amino-3(S)-hydroxy-6-methyl-N-[2-(2-pyridyl)ethyl]heptanamide (Compound No. 261)

The title compound was obtained by the same processes and treatments as in Example 24, melting at 128°-133° C., [α] 23 -34.3° (C=0.3, methanol).

Elemental analysis: Calculated for C 44 H 52 N 6 O 7 : C, 68.02%; H, 6.75%; N, 10.82%. Found: C, 67.35%; H, 6.77%; N, 10.56%.

Claims

23 · 1 independent · depth 3

23 granted claims

›1.independentA compound of the formula (I): R.sup.1 CO--NH--CH(R.sup.2)--CONH--CH(R.sup.3)--X (I) wherein: R.sup.1 represents a group of formula R.sup.13 --CH(NHR.…+22

›2.↳ 1A compound as claimed in claim 1, wherein: R.sup.2 represents an imidazolylmethyl group and is attached to a carbon atom having the S-configuration; R…d2

›3.↳ 1N-(2 -methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucyl]am ino-3(S)-hydroxy-6-methylheptanamide of the formula of claim 1.d2

›4.↳ 1N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucy l]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol of the formula of claim 1.d2

›5.↳ 1N-{4(S )-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-thienyl)-DL-alanyl]amin o-3(S)-hydroxy-6-methyl-heptanoyl}-L-isoleucinol of the formula of …d2

›6.↳ 1N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1 ,3-thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide of the form…d2

›7.↳ 1N-{4(S)-[N-benzyl oxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-DL-alanyl]amino-3( S)-hydroxy-6-methylheptanoyl}-L-isoleucinol of the formu…d2

›8.↳ 14(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-thiazolyl)-D L-alanyl]amino-3(S)-hydroxy-6-methyl-N-(2-morpholinoethyl)heptanamide of the formu…d2

›9.↳ 1N-{4(S)-[N-benzyloxyc arbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyridyl)-L-alanyl]amino-3(S)-hydroxy-6 -methylheptanoyl}-L-isoleucinol of the formula of cl…d2

›10.↳ 1N-(2-methylbutyl)-4(S)-{N-[2-(2-methoxyethoxy)ethoxyca rbonyl]-3-(1-naphthyl)-L-alanyl-L-histidyl}amino-3(S)-hydroxy-6-methylhepta namide of the formu…d2

›11.↳ 1N-ethyl-4(S)-[N-benzyloxycarb onyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanam ide of the formula of claim 1.d2

›12.↳ 1N-sec-butyl-4(S)-[N-benzyl oxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylh eptanamide of the formula of claim 1.d2

›13.↳ 1N-isobutyl-4(S)-[N-benzyloxycarbo nyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanami de of the formula of claim 1.d2

›14.↳ 14(S)-[N-benzyloxycarbonyl -3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methyl-N-(2-methyl butyl)heptanamide of the formula of claim 1.d2

›15.↳ 1N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphth yl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol of the formula of claim 1.d2

›16.↳ 11-{4(S)-[N-benzyloxycar bonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptano yl}-L-leucinol of the formula of claim 1.d2

›17.↳ 12-[2-{4(S)-[N-benzyloxycarbonyl-3-(1- naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamido}ethyl] -1-methylpyrrolidine of the formula …d2

›18.↳ 13-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl) -L-alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamido}-6-methylheptan -1,3-diol of the formula of cl…d2

›19.↳ 1N-(1-ethyl-2-pyrrolidinylmethyl) -4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hy droxy-6-methylheptanamide of the formula …d2

›20.↳ 1A method of treating angiotensin-induced hypertension in a mammal by administering to said mammal an effective amount of a renin inhibitor, wherein sa…d2+3

›21.↳ 20A method as claimed in claim 20, wherein: R.sup.2 represents an imidazolylmethyl group and is attached to a carbon atom having the S-configuration; R.…d3

›22.↳ 20A method as claimed in claim 20, wherein said renin inhibitor is selected from the group consisting of: N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-…d3

A method as claimed in claim 20, wherein said renin inhibitor is selected from the group consisting of: N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucy l]amino-3(S)-hydroxy-6-methylheptanamide N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-leucyl]amino-3(S)-hy droxy-6-methylheptanoyl}-L-isoleucinol N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-thienyl)-DL-alany l]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol N-(2-methylbutyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3- thiazol-4-yl)-DL-alanyl]amino-3(S)-hydroxy-6-methylheptanamide N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(1,3-thiazol-4-yl)-D L-alanyl]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(4-thiazolyl)-DL-alanyl ]amino-3(S)-hydroxy-6-methyl-N-(2-morpholinoethyl)heptanamide N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-3-(2-pyridyl)-L-alanyl ]amino-3(S)-hydroxy-6-methylheptanoyl}-L-isoleucinol N-(2-methylbutyl)-4(S)-{N-[2-(2-methoxyethoxy)ethoxycarbonyl]-3-(1-naphthyl )-L-alanyl-L-histidyl}amino-3(S)-hydroxy-6-methylheptanamide N-ethyl-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino- 3(S)-hydroxy-6-methylheptanamide N-sec-butyl-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]am ino-3(S)-hydroxy-6-methylheptanamide N-isobutyl-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]ami no-3(S)-hydroxy-6-methylheptanamide 4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)-hyd roxy-6-methyl-N-(2-methylbutyl)heptanamide N-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)- hydroxy-6-methylheptanoyl}-L-isoleucinol 1-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)- hydroxy-6-methylheptanoyl}-L-leucinol 2-[2-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3( S)-hydroxy-6-methylheptanamido}ethyl]-1-methylpyrrolidine 3-{4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L-alanyl-L-histidyl]amino-3(S)- hydroxy-6-methylheptanamido}-6-methylheptan-1,3-diol N-(1-ethyl-2-pyrrolidinylmethyl)-4(S)-[N-benzyloxycarbonyl-3-(1-naphthyl)-L -alanyl-L-histidyl]amino-3(S)-hydroxy-6-methylheptanamide.

›23.↳ 20A method as claimed in claim 20, wherein said mammal is human.d3

Classifications

12 codes

IPC · International Patent Classification

Section A — Human necessities

A61K38/55
A61K38/00
A61K38/05
A61P43/00
A61K38/06
A61P9/12

Section C — Chemistry; metallurgy

C07K5/083
C07F9/30
C07K14/81
C07K5/02

USPC · US Patent Classification

514/18530/331

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

Pendency

2.7 y

979 days filing → grant

Office actions

on the grant's record

Examiner

Delbert R. Phillips

art unit 153 · TC 1500

Law firm

Law firm · Log in to unlock

Citations: 14 back · 16 forward

Chain of title

⤢ drag to zoom

Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Worldwide family

22 members · 12 offices

this patentIP5 & PCTother officessolid = grantedhover for detail · click to open

Members

DOCDB simple family 11990054

Offices

US · EP · JP · KR

Granted

4 of 22

grant date present

Non-English titles

shown as filed, never translated

›IP5 & PCT — 6 members

Office	Publication	Kind	Published	Filed	Status	Title
USthis patent	US-4698329-A	A	6 Oct 1987	30 Jan 1985	granted	New renin-inhibitory peptides and their use
EP	EP-0152255-A2	A2	21 Aug 1985	4 Feb 1985	published	Renin hemmende Peptiden und deren Anwendungde
EP	EP-0152255-A3	A3	16 Jun 1987	4 Feb 1985	published	New renin-inhibitory peptides and their use
JP	JP-S60163899-A	A	26 Aug 1985	3 Feb 1984	published	Renin-inhibiting peptide
KR	KR-850006008-A	A	28 Sep 1985	2 Feb 1985	published	레닌 억제 펩타이드의 제조방법ko
KR	KR-910007576-B1	B1	28 Sep 1991	2 Feb 1985	granted	레닌 억제 펩타이드의 제조방법ko

›Other offices — 16 members

Office	Publication	Kind	Published	Filed	Status	Title
CA	CA-1267498-A	A	3 Apr 1990	4 Feb 1985	granted	Renin-inhibitory peptides and their use
DK	DK-47285-D0	D0	1 Feb 1985	1 Feb 1985	published	Renininhiberende peptider og anvendelsen derafda
DK	DK-47285-A	A	4 Aug 1985	1 Feb 1985	published	Renininhiberende peptider og anvendelsen derafda
ES	ES-540110-A0	A0	1 Jun 1987	1 Feb 1985	published	Un procedimiento para preparar nuevos peptidos hipotensivos.es
ES	ES-8706167-A1	A1	1 Jun 1987	1 Feb 1985	published	Un procedimiento para preparar nuevos peptidos hipotensivos.es
FI	FI-850429-A0	A0	1 Feb 1985	1 Feb 1985	published	Nya renin-inhiberande peptider och deras anvaendning.fi
FI	FI-850429-A7	A7	4 Aug 1985	1 Feb 1985	published	Uudet reniiniä inhiboivat peptiidit ja niiden käyttö.fi
FI	FI-850429-L	L	4 Aug 1985	1 Feb 1985	published	Nya renin-inhiberande peptider och deras anvaendning.fi
HU	HU-T38105-A	A	28 Apr 1986	1 Feb 1985	published	Process for preparing new renine inhibitor peptides and pharmaceutical compositions containing such a peptide as active substance
HU	HU-198951-B	B	28 Dec 1989	1 Feb 1985	published	Process for producing new renin inhibiting peptides and pharmaceutical compositions comprising such peptides as active ingredient
NO	NO-850397-L	L	5 Aug 1985	1 Feb 1985	published	Renininhiberende peptiderno
NO	NO-167744-B	B	26 Aug 1991	1 Feb 1985	published	Analogifremgangsmaate til fremstilling av renininhiberendepeptider.no
NO	NO-167744-C	C	4 Dec 1991	1 Feb 1985	published	Analogifremgangsmaate til fremstilling av renininhiberendepeptider.no
PT	PT-79917-A	A	1 Mar 1985	1 Feb 1985	published	Process for preparing new renin- inhibotory peptides and their use
PT	PT-79917-B	B	5 Feb 1987	1 Feb 1985	published	Process for preparing new renin- inhibotory peptides and their use
SU	SU-1739852-A3	A3	7 Jun 1992	1 Feb 1985	granted	Method for synthesis of peptides or their pharmaceutically acceptable salts

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.